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1. SUMMARY
Substance abuse is a major health problem world-wide. Whatever the 
treatment goal, be it abstinence, ‘controlled* use, or relapse prevention, the 
outcome from both pharmacological and non-biological treatments remains 
disappointing. In recent years, animal experiments have suggested that the 
reinforcing properties o f drugs o f abuse are critical to drug-seeking 
behaviour. Dopaminergic fibres running from the ventral tegmental area to 
the nucleus accumbens play a central role in the mediation o f alcohol-induced 
reinforcement. Notably, 5-hydroxy-tryptamine^ (5-HTf) receptor antagonists, 
which antagonize dopaminergic activity in the nucleus accumbens, have been 
shown to inhibit ethanol consumption in a free-choice paradigm, and to 
attenuate the reinforcing effects o f amphetamine in some animal models. 
Obviously, the demonstration o f a similar effect in humans would have 
important clinical implications for the treatment o f substance abuse. In 
humans, however, reinforcement is difficult to measure directly. Nevertheless, 
the pleasurable subjective effects o f drugs o f abuse are important behavioural 
correlates o f the reinforcement process. In the present thesis I  investigated the 
effects o f 5-HT^ receptor antagonists on the subjective positive effects o f 
alcohol and amphetamine. In addition, the independent and interactive effects 
o f a 5-HT^ antagonist and amphetamine on hunger, caloric intake and 
macronutrient selection, and cognitive performance was studied. The 5-HT5 
antagonist, ondansetron, reliably reduced the pleasurable subjective effects 
and the desire to drink alcohol. In addition, evidence was provided to
demonstrate that ondansetron did not simply reduce the absorption o f alcohol, 
as it has the ability to slow gut motility. Thus, these experiments are the first 
clear evidence that 5-HT5 antagonists can decrease the reinforcing properties 
o f alcohol in humans. It is, however, important to point out that alcohol 
consumption was not measured directly, and it is possible, as has been 
demonstrated with other drugs such as cocaine, that blockade o f 
reinforcement can, paradoxically, increase consumption and the subject works 
harder to obtain the drug. While repeated dosing with ondansetron also 
attenuated some positive subjective effects and the anorexic properties o f 
d-amphetamine; in contrast, a single dose o f the second generation 5-HT^ 
antagonist, GR 68755, was without effect on mood, hunger, satiety, and food  
intake. This suggests that, as in recent electrophysiological studies, 5-HT^ 
antagonists may only influence the reinforcing properties o f drugs which 
indirectly facilitate dopamine neurotransmission via 5-HT activity at 
excitatory pre-synaptic 5-HT^ receptors, and are not effective against drugs 
which, simply, cause the direct release o f dopamine from nerve terminals and 
do not increase dopamine cell firing transynaptically. It is, therefore, possible 
that the successful attenuation o f amphetamine-induced subjective state and 
hunger by ondansetron was due to kinetic effects, which presumably became 
more manifest with repeated rather than single dosing, possible post-synaptic 
effects at 5-HT5 receptors or interactions with other neurotransmitter systems 
which are, at present, poorly understood, or chance. Further studies are 
needed, however, to investigate the effectiveness o f a pharmacological range 
o f doses o f 5-HT y antagonists on amphetamine-induced behaviour. GR 68755
was without effect on the natural increase in subjective feelings o f hunger over 
time following an overnight fast, and the pattern o f caloric intake and 
macronutrient selection was similar to placebo. D-amphetamine reliably 
reduced hunger, and this was shown using a test meal to lead to a global 
decrease in caloric intake and no macronutrient was selectively spared or 
consumed. Interestingly, both GR 68755 and amphetamine alone improved 
cognitive performance but this effect was not additive suggesting different 
neurotransmitter systems may be involved. In future, I  intend to extend this 
human laboratory work by uncovering the therapeutic range o f ondansetron 
with respect to decreasing the positive subjective effects including the desire 
to drink in alcohol abusers, and to investigate what impact this has on alcohol 
consumption. I f  these experiments are successful a clinical trial would be 
warranted
2. An overview of alcohol and amphetamine related problems 
2.1 Introduction
Alcohol misuse is a major and growing health problem world-wide 
(Armyr et al., 1982; Hein and Pittman, 1989; Karrenbrock, 1990; Helzer and 
Canino, 1992). While modest drinking is socially accepted in most cultures, 
there has been, in recent years, growing public awareness about the effects of 
excessive alcohol consumption on both physical and mental health, and safety. 
In Britain, up to one fifth of all males admitted to General Hospitals may have 
alcohol problems (Jarman and Kellet, 1979). In addition, two illustrative 
clinical surveys have suggested that between 10% and 15% of psychiatric 
hospital in-patients are alcohol abusers (Glass and Jackson, 1988; Johnson, 
1990 respectively). One third of drivers killed in road traffic accidents have 
blood alcohol levels above the legal limit (Department of the Environment,
1976), and excessive drinking is highly correlated with domestic violence 
(Orford, 1979; Smith, 1989), public order offences (Tuck, 1989), and homicide 
(Gillies, 1976; Gudjonsson and Petursson, 1990). It is, therefore, of concern 
that excessive drinking may be on the increase: for example, the Scottish 
Council on Alcohol (1988) reported that alcohol consumption per head of 
population rose from 6.9 litres in 1975 to 9.1 litres in 1985. In the United 
States the situation is equally problematic, with an increasingly greater 
proportion of the health care budget being devoted to the management of 
alcohol-related problems: from $136 billion in 1990 to an estimated $150 
billion in 1995 (Secretary of Health and Human Services, 1990).
In Britain, unlike the United States, there is no nation-wide system, 
such as the Drug Abuse Warning Network (DAWN), for tracking morbidity 
and mortality due to drug abuse. Nevertheless, the media having abstracted 
without caution from the United States situation, have excited the public with 
shocking stories attributable to the use of stimulants drugs; notably, 
amphetamine and amphetamine-like substances, and ‘‘crack** cocaine. In 
particular, stimulants have been associated with the spread of the human 
immunodeficiency virus (HIV), gang violence, and the sudden death of 
teenagers at “rave** parties where the use of the amphetamine-like substance 
3,4-methylenedioxymethamphetamine (MDMA or ecstasy) is almost endemic 
(Royal College of Psychiatrists, 1987). It is now widely accepted that 
amphetamine misuse occupies a dominant position in the UK drug scene 
(Drugs Branch Inspectorate, 1987). In 1988, Stimson and co-workers 
reported that, despite striking regional variations, about 15% of attenders at 
needle exchange programmes misused amphetamines; of these, more than half 
were estimated to have injected within four weeks of presenting. It has been 
suggested that the increased propensity of amphetamine misusers to inject with 
friends (Klee, 1992) and to be sexually active afterwards (Andreason et al, 
1991; Kail and Olin, 1991) may lead to greater risk of HIV seropositivity 
among amphetamine users compared with those who inject other drugs (Harris 
et al, 1991).
In the United States, amphetamine abuse reached epidemic levels in the 
1970’s, and then subsided - over 10 billion 5 mg tablets were produced 
(Grinspoon and Hedbloom, 1975). Recently, there has been an outbreak of
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âf-amphetamine abuse on the Pacific Coast, Hawaii, and in some communities 
stateside (U.S. National Institute on Drug Abuse {NIDA} 1989 and 1990) but 
fears of a national crisis have, as yet, failed to materialize (CHO, 1990).
2.2. Treatment Programmes for alcohol and amphetamine
The last twenty years has seen changes in the treatment of alcoholism. 
Intensive in-patient programmes, for all but the most intractable of cases, 
rapidly fell out of favour following criticism by the WHO Expert Committee 
(1980) of its expense and lack of efficacy at preventing relapse. Emphasis 
shifted towards the “traditional” method which stressed psychotherapy, 
education, and social manipulation. Recently, there has been an expansion in 
programmes incorporating the Alcoholics Anonymous (AA) ideology - the best 
known of these being the Minnesota model (Cook, 1988). Partly as a reaction 
to this AA model, which has aroused much controversy, a 
cognitive-behavioural approach (i.e. training the alcoholic in self-control 
techniques) has become increasingly popular (Sanchez-Craig, 1990). In the UK 
early identification of the problem drinker (i.e. an individual whose excessive 
alcohol consumption gives rise to medical, psychological, or social problems) 
by the family practitioner (Pollack, 1989) using a screening questionnaire such 
as the ‘CAGE* (Roche et al., 1984) followed by treatment with brief 
counselling (Edwards, 1977) and specialist support if necessary has been shown 
to be of benefit (Drummond et al., 1990). In the CAGE* questionnaire, 
individuals are asked: 'Have you ever felt you should cut down on your 
drinking? ” 'Have people annoyed you by criticizing your drinking? ” Have
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you ever felt bad or guilty about your drinking? ” “Have you ever had a drink 
first thing in the morning to steady your nerves {eye-openeryt ” If two or more 
positive answers are taken to indicate problem drinking, most problem drinkers 
are identified; nevertheless, specificity is not as good with a false-positive rate 
of about 25% (Mayfield et al, 1974). Treatment is directed at motivating 
(Prochaska and Di Clemente, 1986) the individual to decrease or cease alcohol 
consumption altogether.
Irrespective of the type of treatment programme, and each has its 
advocates, response to treatment remains poor. The influential Rand Report 
(Armor et al., 1976) which compared 45 treatment centres in the USA showed 
that only a quarter of alcohol abusers remained abstinent after six months, 
although the majority had reduced their drinking. Unfortunately, the findings of 
more recent studies have been hard to interpret for three reasons. Firstly, 
advocates of each particular programme have been most successful at 
demonstrating its greater efficacy over other methods in their own clinics. 
Secondly, because patients usually have a choice of treatment programmes, 
they could reasonably be expected to select one which suited them best 
(Saunders, 1989). Thirdly, it has been suggested that private treatment 
programmes may be more accessible to alcoholics with good prognostic 
features such as employment and favourable psycho-social circumstances to the 
exclusion of those with personality difficulties (especially psychopathy), 
depression, or hypochondriasis (Clement and Kahn, 1990). These observations 
question whether specialized or private treatment centres can empirically
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investigate themselves when their set-up is, naturally, more favourable towards 
their own techniques (Peele, 1990). It remains unclear whether controlled 
drinking is a more realistic goal than abstinence (see Edwards, 1986 for a 
synopsis).
The extent of morbidity and mortality as a consequence of amphetamine 
use in Britain is largely unknown. For example, Stimson and co-workers (1988) 
found that only 10% of amphetamine injectors were receiving specialist help; in 
contrast, about 60% of heroin users were receiving treatment. Even in the 
United States, data on trauma attributable to amphetamine use is not readily 
available. Nevertheless, an illustrative study of eight American cities (San 
Diego, San Francisco, Dallas, Phoenix, Los Angeles, Seattle, Denver, and 
Philadelphia) reported to DAWN showed that between 1985 and 1989, 
emergency room admissions for amphetamine toxicity almost doubled in the 
month of March from 1,370 to 2,135; in April for the same years, data from 
six states (San Diego, San Francisco, Los Angeles, Philadelphia, Oklahoma 
City, and Phoenix) showed that deaths rose from 65 to 180 (NIDA, 1989 and 
1990). Amphetamine use among teenagers and adolescents appears to be on 
the increase with California having, perhaps, the highest rates. In a 
representative study of six hundred and fifty nine 16 to 24 year olds admitted to 
the University of California at Davis Trauma service, 7% tested positive for 
amphetamine (Helschober and Miller, 1979). Interestingly, while a detailed 
retrospective case study of 127 patients attending a casualty department with 
amphetamine toxicity revealed that one-tenth presented with physical 
complaints suggestive of increased catecholamine activity such as palpitations.
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chest pain, seizures, and more rarely, cardiac ischaemia and cerebrovascular 
accidents, the majority (57%) complained of a deterioration in mental state - 
agitation, confusion, delusions, hallucinations, and suicidal ideas were common 
(Derlet et al, 1989). The high rate of perceptual abnormality was not surprising 
as paranoid psychosis is a well recognized complication of chronic 
amphetamine abuse (Connell, 1958; Ellinwood, 1967 and 1971).
Like other drug abusers, motivational techniques have been used to 
encourage cessation of amphetamine misuse (Prochaska and Di Clemente, 
1986; Van Bilsen and Von Emst, 1986). After detoxification, relapse 
prevention strategies which may include the avoidance of ‘high risk* situations, 
and breaking contact with acquaintances who misuse drugs are encouraged. In 
human laboratory experiments, extinction to cues have also been tried 
(Fischman and Foltin, 1991). In Britain, amphetamine misusers are seldom 
enrolled into residential, rehabilitation programmes. There is no reliable, 
empirically based information on the outcome of treatment.
In summary, early identification of the alcoholic in the community 
followed by counselling appears to be a pragmatic approach to treatment. 
In-patient treatment should, perhaps, be reserved for those with serious medical 
or psychiatric problems, and a management plan, particularly if treatment is to 
be long-term, has to be carefiilly thought out. Psychoanalytical programmes 
have been ineffective, and none of the other psychological regimes stands out 
from the rest. The alcoholic should be guided to chose one which suits best.
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Prolonged abstinence following treatment is uncommon and may be an 
unrealistic goal. In Britain, it is obvious that there is a pressing need for a 
nation-wide database to monitor morbidity and mortality following 
amphetamine use and misuse, and to evaluate treatment outcome. Though 
extrapolation from the United States situation must be cautious, there is 
concern that the use of amphetamine and amphetamine-like substances may be 
growing in urban areas with increasingly younger children becoming involved, 
and that this may be an important contributory factor to the spread of the HIV 
virus.
2.3. Pharmacological treatments for alcohol abuse
In the last two decades, pharmacological treatments for drug addiction 
have become increasingly popular. In general, the main focus of medical 
attention has been with ameliorating the withdrawal symptoms of drugs of 
abuse including alcohol. It was held, perhaps naively, that uncovering how 
neurones adapt to these drugs would explain the biological determinants of the 
addictive process. At present, the pharmacological management of alcohol 
withdrawal remains central to drug treatment approaches.
The search for specific antagonists to the acute effects of alcohol has 
proved fiuitless. The anecdotal ‘sohering-up ’ properties of caffeine cannot be 
explained by its specific psychotropic actions (Nuotto et al, 1982). 
Additionally, naloxone’s ability to alleviate alcohol-induced coma can, simply, 
be attributed to amelioration of the exacerbating effects of endogenous opioids
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(Dole et al., 1982). The benzodiazepine antagonist RO 15-4513 (ethyl-8-azido- 
5,6-dihydro-5 -methyl-6-oxo-4Himidazo[ 1,5 a] [ 1,4]benzodiazepine-3 -carboxylate) 
reduces some of the behavioural effects of ethanol, and inhibits ethanol- 
stimulated chloride ion fluxes. It, however, does not reverse the lethal effects of 
alcohol in animals, and its epileptogenic properties mitigates against safe 
therapeutic use in humans. RO 15-4513 is not a specific antagonist to the acute 
effects of alcohol; it also antagonizes the action of other sedatives including 
barbiturates (for a brief review, see Lister and Nutt, 1987).
Traditionally, the avoidance of aversive stimuli or withdrawal symptoms 
was considered to be critical to maintaining drug-seeking behaviour. Thus, it is 
not surprising that the use of pharmacological agents to condition aversive 
responses to drinking was a major treatment goal. Emetine-induced nausea was 
used almost half a century ago to prevent drinking, and more recently, there 
was a brief flirtation with apomorphine. Lately, disulfiram and similar chemical 
agents have been used to condition aversive responses (Kreek, 1987). The 
therapeutic efficacy of disulfiram is doubtful. It has mainly been shown to be of 
benefit among alcohol abusers who attend regularly, have a high expectation of 
success, and who are well supported by their spouse and family (Kitson, 1977); 
that is, the sort of abuser most likely to refi'ain from drinking without them. 
Hence, producing aversion may, in itself, be insufficient to prevent the 
reinstatement of drinking. It has, therefore, been argued that giving disulfiram 
is nothing more than administering a ‘psychologicalpilV - each time it is taken.
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the alcohol abuser is reminded of the therapeutic bond and treatment contract 
with his or her therapist.
Historically, another important approach has been to break the vicious 
cycle of alcohol-induced dysthymia leading to increased drinking by prescribing 
lithium - a drug whose antidepressant properties have been attributed to 
stabilization of 5-Hydroxytryptamine (5-HT) neurotransmission by 
simultaneously increasing 5-HT brain levels and decreasing the number of 
5-HT receptors (Bunney and Gerald-Bunney, 1987). Depressed drinkers 
benefited most with improved mood and a reduction in alcohol consumption 
(Merry, et al., 1976; Rounsaville et al., 1982), and a decrease in the urge to 
drink (Judd and Huey, 1984). Lithium therapy was abandoned because the 
erratic fluid intake of alcohol abusers often precipitated toxicity. Interestingly, 
preliminary reports suggest that other drugs with actions on 5-HT 
neurotransmission such as fluoxetine may also reduce alcohol consumption 
(Naranjo et al., 1990).
2.4. Pharmacological approaches to amphetamine misuse
The principal pharmacological activity of amphetamine at clinically 
relevant doses is to produce a rise in the availability of dopamine at the synaptic 
cleft by potentiating release; additionally, there is some enhancement of 
neurotransmission at both noradrenergic and 5-HT receptors, and it is a weak 
inhibitor of amine re-uptake (Carlsson, 1970; Heikkila et al, 1975). The 
psychological effects of amphetamine including its ability to act as a reinforcer.
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and thereby maintain drug-seeking behaviour (see below for details), appear to 
be mediated by dopamine. While specific antagonists at both the Dj and D2 
receptor subtypes of dopamine attenuate amphetamine-induced reinforcement 
in animals (Yokel and Wise, 1976), and D2 receptor blockers inhibit the 
mood-inducing effects of amphetamine in humans (Jacobs and Silverstone, 
1986), the risk of triggering extrapyramidal dysfunction, especially tardive 
dyskinesia, precludes their long-term use to treat amphetamine abuse. 
Emergency or short-term use of a D2 receptor antagonist is sometimes 
necessary to reduce the severity and duration of amphetamine-induced 
psychotic symptoms.
3. Synopsis of new approaches to drug addiction: behavioural 
correlates - the importance of reinforcement and the 
discriminative stimulus effect
In recent years, conditioning and learning processes have been 
recognized to be critical in directing, sustaining, and controlling, drug seeking 
behaviour. For a drug to have abuse potential it must have two essential 
properties which allow it to act as a psychostimulant (Wise and Bozarth, 1987).
Firstly, it should have the ability to act as a positive reinforcer, whereby 
the likelihood and frequency of drug-seeking behaviour is increased when the 
drug is presented. In this respect, most abused drugs have psychostimulant 
properties.
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Secondly, it must be able to produce an internal stimulus (discriminative 
cue) that can be readily distinguished by the animal. In this way, characteristic 
subjective effects of classes of drug can be readily recognized, and 
differentiated from other drugs and the non drug condition.
In addition, some abused drugs (e.g. alcohol) may possess aversive 
properties but this of less importance in maintaining drug-seeking behaviour. 
That is, in the naive individual, mild unpleasant effects, such as dysphoria or 
anxiety, may occur when the drug is taken. Nevertheless, with further 
exposure, the appreciation of its positive subjective effects strengthen 
considerably and little or no aversive symptoms are experienced provided the 
individual does not become intoxicated. Alcohol dependent individuals usually 
experience few positive subjective effects on drinking but develop severe and 
sometimes prolonged withdrawal symptoms such as anxiety and depression on 
abstaining. Thus, avoidance of withdrawal may play a part in shaping 
alcohol-seeking behaviour in alcoholics.
In summary, four principles govern the new approach to drug addiction. 
They are: (i) drug-seeking behaviour is common to all drug addictions; (ii) all 
drugs of abuse can act as psychostimulants; (iii) the reinforcing and 
discriminative stimulus effects of drugs of abuse are critical to directing, 
controlling, and maintaining drug-seeking behaviour; and (iv) the avoidance of
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withdrawal symptoms or aversive stimuli may influence drug-seeking behaviour 
in some classes of drug such as alcohol (Stolerman, 1992).
4. SCIENTIFIC BASIS OF DRUG-SEEKING BEHAVIOUR
4.1. Background and concepts of behavioural measures
There has been much confusion in the literature because the terms 
reward and reinforcement have been used interchangeably. Reinforcers 
produce response-contingent stimulation; that is, they enhance or sustain the 
probability that the response will be repeated (Skinner, 1932). This must be 
differentiated from priming effects where stimulation increases the incentive or 
drive to carry out the response in a non response-contingent manner. In this 
respect, and in the present thesis, reward refers to the integral activity of both 
priming and reinforcement processes.
In animal experiments, electrical self-stimulation of certain brain reward 
sites produce a rise in rates of responding over a dynamic range which is in 
proportion to the strength of the stimulus. Eventually, a plateau is reached, 
whereby greater stimulation leads to no change in response above or below a 
certain level. This plateau, or asymptotic range, is not related to the reinforcing 
value of the stimulus but gives the limit of responding for that specific brain 
region (Miliaressis and Malette, 1987; Waraczynski et al., 1987). Limits of 
responding vary between brain regions (Prado-Alcala and Wise, 1984). The 
asymptotic range is dependent on motor fimction and can be impaired by 
simultaneous stimulation at different sites (Miliaressis and Rompre, 1987); in
20
contrast, the dynamic range is a reflection of the reinforcing value of a 
particular stimulus or drug of abuse. Early experiments which used 
rate-dependent measures (or reward thresholds) have been heavily criticized 
because it was difficult to determine if, and by how much, variations in 
response rate for a given putative reinforcer could be attributed to changes in 
either the asymptotic or dynamic range, or both (Valenstein, 1964). For 
instance, reward thresholds could be defined in three ways: a cut-off point 
above which stimulation produces responses more than 50% of the time, half 
the asymptotic level, or the minimum stimulation needed to maintain rates of 
responding above the baseline. The important problem was that while 
asymptotic and dynamic rates could only be segregated at the asymptotic point 
(i.e. at a point of stasis), variations in the dynamic range always influenced the 
asymptotic level. Thus, differentiation between the effect of the reinforcer on 
response, and the limit of responding to it was not possible, and discrimination 
between responses which occurred in the asymptotic or dynamic ranges was 
unclear (Valenstein, 1964). Nowadays, the curve shift paradigm is the 
psychometric measurement of choice. For instance, the plot of response rate Vs 
the log of the stimulation intensity is usually sigmoidal. While a biologically 
significant shift to the right (i.e. to higher stimulation intensities) indicates a 
decrease in the reinforcing effect of the stimulus or drug of abuse, a shift to the 
left implies the converse. Notably, experimental noise can sometimes produce 
small but biologically insignificant lateral shifts. Increased performance capacity 
leads to upward shifts, and vice versa. In essence, these curves are analogous 
to dose-response relationships in pharmacology: here, the stimulus intensity is
21
the drug dose. In summary, the curve shift paradigm has been used to identify 
and chart the relative contribution of a range of brain sites to the reinforcement 
process, and to evaluate the differential strengths of a variety of reinforcers at 
such sites (Diagram 1).
100-1
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w 60-
Q. 40-
20 -
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Log Hz
Diasram 1: is a rate-frequency ‘curve-shift whereby response is plotted against the log o f 
the number o f pulses in a burst o f ‘reinforcing ’ stimulation. Filled circles depict the baseline 
curve. A decrease in reinforcing stimulation, for example by the administration o f a 
moderate dose (0.25 mg/kg) o f the D2 receptor antagonist, pimozide, shifts the curve to the 
right (open squares). A t higher doses, 0.5 mg/kg, motor impairment o f responding shifts the 
curve downwards (open triangles).
By courtesy o f Stellar, J.R. (1983) and Oxford University Press.
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4.2. Conditioned Place Preference (CPP)
The CPP paradigm is a well known rate independent method for 
assessing the reinforcing impact of electrical stimulation, drugs of abuse, food, 
and taste preference. Unlike self-stimulation which is dependent on eliciting 
stimulus contingent responding, CPP relies on the ability of the reinforcer to 
cause approach behaviour.
In CPP a neutral stimulus is paired with the reinforcer such that the 
stimulus itself becomes capable of serving as a reinforcer {secondary 
conditioning {Diagram 2}). While there is considerable evidence that CPP is 
mediated by dopaminergic pathways from the VTA to the nucleus accumbens, 
other neurochemicals and non-dopaminergic mechanisms, as in intracranial 
self-stimulation (ICSS) described below, may play a modulatory role. 
Dopamine receptor antagonists injected into the nucleus accumbens decrease 
CPP induced by drugs of abuse such as amphetamine (Mackey and Van der 
Kooy, 1985; Mithani et al., 1986); additionally, lesions in the tegmentum 
(Bechara and Van der Kooy, 1986) and nucleus accumbens (Spryaki et al., 
1982a) can reduce CPP, while destruction of central noradrenergic fibres does 
not (Spryaki et al, 1982a and b).
23
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grid floor photocell
Diagram 2: A simple CPP box has two different enclosed compartments separated by a 
guillotine. While one compartment is predominantly featureless, the other has a grid floor 
and chequered walls. The animal receives the reinforcer (e.g. a drug o f abuse) in one 
compartment, and vehicle in the other. After ‘pairing’ the animal in this way, the guillotine 
is lifted. The animal can now roam freely between the two compartments. The amount o f time 
the animal spends in each compartment can be measured by light beams or photoelectric 
cells. Treating the animal with a dopamine antagonist reduces the time it spends in the 
chamber in which it was ‘paired’ with the drug o f abuse.
With the kind permission of Stolerman, I. (1992) and Elsevier Science Publishers Ltd
24
4.3. Mapping brain reinforcement pathways and Intracranial 
self-stimulation (ICSS)
Reinforcement is critical to the direction, control, and maintenance of 
drug-seeking behaviour. Neuroanatomical pathways involved in reinforcement 
have been mapped by electrical stimulation of specific brain regions, and the 
action of drugs of abuse at certain receptor sites.
Using movable electrodes to demarcate the boundaries of the 
reinforcement circuit, Schmitt et al (1974) discovered that aminergic fibres in 
the mesencephalon - a combination of serotonergic, dopaminergic, and 
noradrenergic fibres - were associated with reward. Stimulation of other 
regions, notably the periacqueductal grey, was aversive. The experiments of 
Corbett and Wise (1980) provided evidence that dopaminergic fibres were 
essential to reinforcement as low thresholds for responding were found in the 
ventral tegmentum area (VTA); further, high threshold reinforcement sites 
were located superior to the VTA. This suggests that the mesencephalic 
reinforcement circuits are extensions of, or in close association with, the 
tegmental network (Rompre and Miliaressis, 1985). While stimulation of the 
locus coeruleus produced no reinforcement suggesting that noradrenergic 
pathways were not primarily involved with reinforcement, noradrenergic 
pathways were found to be important for priming the animal for locomotion, 
thus enabling the expression of the response.
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ICSS is a special type of operant conditioning, whereby the animal 
learns to self-administer electrical stimulation as a surrogate to a natural 
reinforcer such as food or water. ICSS has been demonstrated throughout the 
length of the medial forebrain bundle (for a review see Phillips and Fibiger, 
1989). The findings of ICSS experiments suggest that dopaminergic fibres, 
particularly in the ventral tegmental, may mediate reinforcement process, and 
that the principal sites extend from the anterior region of the nucleus 
accumbens to the level of the mesencephalic nucleus of the trigeminal nerve 
(Rompre and Boye, 1986). Other strong candidates for reinforcement sites 
include the medial prefrontal cortex and cingulum (Silva et al., 1982). The 
lateral hypothalamus (Edmonds and Gallistel, 1974; Miliaressis et al., 1986), 
septal nuclei (Waraczynski, 1988), amygdala (Gallistel et al., 1985), habenula 
(Nakajima, 1984), and cerebellum (Watson, 1978; Corbett and Wise, 1982) 
have also been suggested as possible sites. In addition, there is evidence that 
other neurochemicals modulate the mesocorticolimbic reinforcement circuit. 
These include: neuropeptides (Crow and Deakin, 1985); cholecystokinin 
{CCK} (Hsiao and Deupree, 1983; Ettenberg and Koob, 1984); 
gamma-aminobutyric acid {GABA} (Kent and Fedinets, 1976; Zarevics and 
Setler, 1981); acetylcholine {Ach} and adrenocorticotrophic hormone 
(ACTH) (Izquidero, 1984). Serotonin systems might also affect the expression 
of reinforcement-seeking behaviour. Para-chlorophenylalanine (PCPA), which 
inhibits 5-HT synthesis, decreases ICSS in the dorsal (Van der Kooy et al., 
1978) and median (Miliaressis, 1977) raphe, hippocampus (Van der Kooy,
1977) and caudate nucleus (Phillips et al., 1976). Notably, the attenuation of
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ICSS in the medial forebrain bundle (MFB) is, temporally, out of phase with 
5-HT depletion suggesting other inter-related neural mechanisms may be 
operating (Stark et al., 1970). Paradoxically, some studies have reported an 
increase in ICSS following PCPA or neurotoxic destruction of the 5-HT system 
(Gibson et al., 1970; Porschel et al., 1973). In addition, self-stimulation of
5-HT fibres which arise from the dorsal raphe is attenuated by serotonin 
blockade (Nakajima, 1984). Thus, it is conceivable that interruption of 5-HT 
activity simply makes the animal work harder to maintain the same level of 
reinforcement. Taken together, this suggests that the 5-HT system plays a 
modulatory rather than a direct role in reinforcement . It is also of note that 
while drug injection studies have suggested acetylcholine may also modulate 
reinforcement, confirmation of this fi"om neuroanatomical studies has not been 
forthcoming (Yoemans et al, 1985). The ways by which non-dopaminergic 
neuronal circuits might influence the putative mesolimbic dopamine reward 
pathway are described in more detail elsewhere (section 5).
4.4. Alcohol-induced reinforcement: further evidence of
dopaminergic involvement
Alcohol, like other drugs of abuse, can function as a reinforcer (Meish, 
1984). It has been suggested that the mesocorticolimbic dopamine system plays 
an important role in the mediation of alcohol-induced reinforcement. For 
instance, in non-deprived (of food and water) rats, dopamine receptor 
antagonists decrease lever-pressing for alcohol (Pfeffer and Samson, 1985;
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Samson et al., 1988b), and diminish home-cage ethanol drinking. 
Non-deprived Wistar rats that have been trained using a two-lever, free-choice, 
self-administration task, whereby the animal is allowed to make a choice 
whether to press one lever to receive nutrients (food and water) or the other to 
get the surrogate reinforcer, show decreases in stimulation-induced responding 
and in the amount of alcohol consumed when the dose of alcohol (within the 
range of 5-10% alcohol content by volume) is reduced; an increase in dose 
produces the opposite effect on both responding and consumption (Samson et 
al., 1988b).
The classical experiments of Overton (1901) - see Lipnick, 1986 for a 
review - suggested that the acute actions of alcohol was dependent on its ability 
to fluidize neuronal membranes, and that tolerance to chronic alcohol 
consumption could be explained by increased membrane rigidity. While this 
view was still held by some investigators until the early 1980’s, it become clear 
that these structural membrane distortions were, in themselves, insufficient to 
explain changes in cell function (Dietrich et al., 1989; Buck et al., 1991).
Neurochemical studies have also been used to segregate the differential 
role of catecholamines in reward. Intravenous ethanol has been shown to 
increase cell firing in the VTA of awake (Gessa et al., 1985) but not 
anaesthetized rats (Mereu et al., 1984). Gessa and co-workers (1985) 
suggested this action was indirect: ethanol suppressed GABA^ neurones that 
were tonically inhibiting the firing of dopaminergic neurones; interestingly, an
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electrophysiological study of oocytes expressing cloned GABA receptor 
subunits has suggested that alcohol-induced GABAergic activity essentially 
takes place at a specific y unit, ttl (Wafford et al., 1991). In rats, the injection 
of dopamine receptor antagonists into the nucleus accumbens leads to a 
reduction in oral ethanol self-administration (Rassnick et al., 1992). In addition, 
administration of a small dose of ethanol increases locomotor activity (Waller 
et al., 1986), raises extracellular levels of dopamine in the nucleus accumbens 
(Imperato and Di Chiara, 1986), and potentiates cation conductance at 5-HT] 
receptors (Peters et al., 1992). In alcohol-preferring P rats that were orally self- 
administering small doses of alcohol, this rise in extracellular dopamine was 
greater than that seen in non alcohol selective strains (Weiss et al., 1992). It is 
worth stressing that the reinforcing effects of alcohol have been demonstrated 
using small doses (3-10% alcohol content by volume). At higher doses, other 
receptor mechanisms, notably GABA^, may have an enhanced 
neuromodulatory role. At intoxicating doses, profound motor impairment 
makes the meaningful interpretation of responding impossible, and there are 
considerable changes at a wide variety of receptor sites. In particular, there is 
further enhancement at GAB A^, and decreased activity at NMDA and Kainate 
receptors and at Voltage-sensitive calcium channels. The finding that rats 
selectively bred to prefer ethanol may, comparatively, release more 
extracellular dopamine on its administration may have implications for the 
study of the genetic basis of alcoholism in humans. In this respect it is of note 
that the A1 allele of the dopamine D2 receptor gene may be over-represented 
in alcoholics (Blum et al, 1990), and that carriers of the A1 allele have fewer
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T>2 receptors than those with the A2 allele (Noble and Blum, 1991); in gainsay, 
these findings have not been replicated by others (Bolos et al, 1990; Parsian et 
al, 1991), and should be regarded as preliminary.
The central role of dopamine in reinforcement has also been supported 
by evidence from functional studies of calcium channel inhibitors (CCI). In 
animals, CCI decrease alcohol preference and intake, presumably by 
antagonizing dopamine-mediated reinforcement and the discriminant stimulus 
effect (Engel, 1988). Nevertheless, reduced ethanol consumption by CCI could 
also be due to taste aversion - a factor which may explain the prolonged 
inhibitory action of Goe 5438 (Pucilowski et al., 1992). CCI may have a 
therapeutic role in the management of alcohol dependence and withdrawal. 
Chronic alcohol exposure leads to up-regulation of voltage-sensitive Ca^"  ^
channels and an increase in intracellular calcium; concomitantly, GABA activity 
is reduced and NMDA sites up-regulated. Thus, chronic alcohol produces 
chemical changes that antagonize the acute effects of alcohol, leading to a state 
of hyperexcitability when it is withdrawn. In animals, CCI attenuate tremor, 
hyperexcitability, and seizures due to alcohol withdrawal (Dolin et al., 1987; 
Bone et al., 1989) by, presumably, redressing some of this chemical imbalance. 
In animals, CCI also inhibits conditioned place preference to other drugs of 
abuse such as cocaine and (/-amphetamine (Fatta et al., 1991; Pucilowski 
1992), and has been shown to reduce the intake and positive subjective effects 
of cocaine (Jaffe 1989) in man, presumably by decreasing its reinforcing 
properties.
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4.5. Neurochemical effects of alcohol on noradrenergic pathways
The effect of ethanol on the locus coeruleus is principally, but not 
always, depressant. Pohorecky and Brick (1977) showed that i.p ethanol at a 
dose of 2g/kg in paralysed rat preparation mostly produced inhibition of cell 
firing; 22% of the cells were activated and 16% were unchanged. In addition, 
when ethanol was directly applied to the neurones attenuation of cell firing was 
almost universal. Ethanol-induced inhibition of cell firing was also seen in 
animals anaesthetized with chloral hydrate (Strahlendorf and Strahlendorf,
1983). From in vitro studies, cell firing is attenuated in brain slices perfused 
with ethanol at concentrations between 1-60 mM (Shefher and Tabakoff,
1984). The main effect of ethanol on noradrenergic pathways is, therefore, 
depressant. The interaction between noradrenergic and dopaminergic 
mechanisms in the expression of reinforcement is discussed below (section 5).
4.6. Amphetamine-induced reinforcement: additional evidence of 
dopaminergic involvement
Rats can be trained to lever press to self-administer amphetamine 
intravenously (Pickens and Harris, 1968; Wise et al, 1976). It is also well 
recognized that dopamine receptor agonists such as apomorphine and piribedil 
administered on their own (Davis and Smith, 1977; Yokel and Wise, 1978), 
and in the presence of (/-amphetamine (Wolverton et al, 1984), can maintain
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responding in rats. While the selective D% agonist, SKF 38393, did not sustain 
responding, pre-treatment with either the D2 antagonists, haloperidol (Davis 
and Smith, 1975) or pimozide reduces responding after an initial increase which 
might reflect a fehound* phenomenon (i.e. an ""extinction burst’") to try and 
overcome the blockade or a reduction in the antagonist’s rate-decreasing 
properties, or both. Yokel and Wise (1985) found that substituting pimozide 
pre-treatment with saline produced similar extinction on responding for 
amphetamine. Importantly, the direct adrenergic agonist, methoxamine (Riser 
and Jones, 1976), and the adrenergic re-uptake blocker, nisoxetine 
(Woolverton, 1987), do not maintain lever pressing; further, adrenergic 
antagonists such as phenoxybenzamine and propanolol have no effect on 
amphetamine-induced responding. Taken together, the D2 receptor appears to 
be more directly involved in amphetamine-induced reinforcement than D%; in 
contrast, the D% receptor may mediate drug discrimination cues to 
amphetamine (for a review see Neilsen and Anderson, 1992). Though 
adrenergic pathways do not appear to mediate amphetamine reinforcement, 
enhanced noradrenergic neurotransmission appears to be important in priming 
and activation of "burst* firing of dopaminergic neurones - assumedly to 
stimulate and maintain cognitive processes during stress or arousal (D’Angio et 
al, 1988) and preserve selective attention (Oades, 1985).
Convincing evidence that central dopaminergic pathways are critical to 
amphetamine reinforcement has been demonstrated by microinjection, CPP, 
and lesion studies. Direct injection of amphetamine into the nucleus accumbens
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produces hyperactivity contingent on the release of endogenous dopamine 
(Pijnenburg et al, 1976; Costall, 1980; Kuczenski et al, 1991). D-amphetamine 
reliably produces CPP (Mithani et al, 1986; Leone and Di Chiara, 1987; White 
et al, 1987), and selective D2 receptor antagonists such as haloperidol (Mithani 
et al, 1986) and a-flupenthixol (Mackey and van der Kooy, 1985) abolish it. 
Further, 6-hydroxydopamine (6-OHDA) lesions of the nucleus accumbens 
attenuates amphetamine self-administration (Lyness et al, 1979; Roberts et al, 
1980; Roberts and Koob 1982). Interestingly, (/-amphetamine also enhances 
control over behaviour expressed by conditioned reinforcers - a role attributed 
to dopamine-mediated incentive learning (Robbins and Koob, 1978; Beninger 
et al, 1981; Robbins et al, 1983). In a classic experiment, Taylor and Robbins 
(1984) showed that thirsty animals could be trained to reliably associate a 
dipper noise (the conditioned stimulus {CS}) with the delivery of water (the 
unconditioned stimulus{US}). Of the two levers in the animals’ cage, one when 
pressed (the conditioned response (CR) lever ) produced the CS and the other 
(the non-conditioned response {NCR} lever) on pressing elicited nothing. The 
trained animals responded more on the CR than the NCR lever. Following 
intra-accumbens injection of (/-amphetamine, responding on the |CR lever was 
increased while no enhancement of lever pressing was seen on the NCR. 
Behavioural specificity was confirmed by demonstrating that increased CR 
responding on the CR lever did not occur without association of the CS with the US, 
Neurochemical specificity was demonstrated by showing that intra-caudate 
injection of (/-amphetamine produced increased responding on the |cR lever 
Biochemical specificity was illustrated by showing that intra-accumbens
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6-OHDA lesions, but not noradrenergic lesions (Cador et al, 1991) stopped the 
rise in responding on the CR following (/-amphetamine (Taylor and Robbins, 
1986); however, following saline infusion (i.e. without amphetamine) 
behavioural control exerted by the CR is not altered. Thus, dopamine 
neurotransmission in the ventral straitum both facilitates and augments 
amphetamine-induced amplification of contingent behaviours, and other 
(i.e. non-dopaminergic), perhaps even limbic mechanisms, may be involved in 
the mediation of responding to naturally conditioned stimuli under non­
contingent (i.e. everyday) circumstances.
4.7. Amphetamine and cognitive performance: from humans to 
important lesion studies in animals
It is well established that physiological doses of amphetamine in humans 
(between 2.5 mg to 30 mg orally) increase speed of response, vigilance and 
attention, motor performance, and learning on tests of memory (Weiss and 
Laties, 1962; Gunne, 1977; Spiegel, 1979; Harvey, 1987). In a recent 
illustrative study, six healthy male volunteers (aged between 21 and 38 years) 
were subdivided into two groups of three. Each subject received active and 
placebo (/-amphetamine (0 or 10 mg/70 kg) twice daily during two trials each 
held on three consecutive days. Placebo and drug were administered 
alternately, and the order of exposure was counter-balanced between the two 
groups. In amongst other subjective ratings of mood, general well-being, and 
social behaviour, subjects performed computerized tests of vigilance, the
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vigilance task, and learning, the digit-symbol substitution task (DSST). 
Subjects showed a significant increase in vigilance and DSST accuracy and in 
performance with no increase in false alarm rates on responding (Kelly et al., 
1991).
It is of interest that lesions studies of the nucleus accumbens have been 
used in an attempt to tease out the differential contribution of noradrenergic 
and dopaminergic pathways to attention and arousal. Cole and Robbins (1987) 
subjected rats with 6-OHDA lesions of the dorsal noradrenergic bundle 
(DNAB), which reduced cortical noradrenaline to within 5% of control levels, 
to systemic and nucleus accumbens infusion of amphetamine and administered 
an adaptation of Leonard’s five choice reaction time test developed for 
humans. These lesioned rats showed no diminution in performance. Though 
sham-operated rats (controls) responded more impulsively following 
amphetamine, there was no impairment of discriminative accuracy; in contrast, 
the lesioned rats showed impairment of discriminative accuracy - an effect 
which was attenuated by the D2 receptor antagonist, | a-flupenthixol. Taken 
together, these results suggest that attention depends on dopaminergic activity 
in the nucleus accumbens, and as was shown in a later experiment (Cole and 
Robbins, 1992), forebrain noradrenergic pathways may be involved in 
controlled or ‘effortful’ processing.
The present thesis contains the first investigation of 5-HT] receptor 
blockers, which oppose dopaminergic activity in the nucleus accumbens, on
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amphetamine-induced changes in reaction time and attention; this investigation 
is made more intriguing by the finding that 5-HTg receptor antagonists may 
have cognitive enhancing properties in animals (Costall et al, 1990), possibly 
by facilitation of acetylcholine neurotransmission (Barnes et al 1989a and b).
4.8. Amphetamine: effects on caloric intake and 
macronutrient selection
From animal studies, there is direct evidence that feeding behaviour is 
largely mediated via complex interactions between dopamine, noradrenaline, 
and 5-HT (which is discussed later). For instance, adrenaline and noradrenaline 
reduce food intake in rats fed high carbohydrate diets (Russek et al, 1976), 
dopamine receptor agonists such as L-dopa (Sanghvi et al, 1975) and piribidel 
(Carruba et al, 1980) diminish feeding in food deprived animals, and the 
anorexic effects of the P-adrenergic agonist, salbutamol, are antagonized by the 
P-adrenergic receptor antagonist, propanolol.
The anorectic properties of amphetamine have been studied for over 
forty years. D-amphetamine enhances the release of both noradrenaline and 
dopamine (Carlsson, 1970). In addition, brain stimulation, lesioning, and 
behavioural studies in animals suggest that it is this increased catecholamine 
availability that is responsible for amphetamine’s ability to suppress food 
intake. Anorexia induced by amphetamine (at a dose of 1.25 mg/Kg) and 
mazindol (7.5 mg/Kg) is blocked by lesions of the ventral noradrenergic bundle
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(Samanin et al, 1977), and disruption of catecholamine synthesis by 
alpha-methyl-para-tyrosine reduces food intake (Baez, 1974). Notably, 
amphetamine-induced anorexia is only partially attenuated by dopamine 
receptor blockade with a-flupenthixol at relatively high (Garattini and Samanin, 
1976) but not at low dosages (Burridge and Blundell, 1979). Hence, it has been 
suggested that noradrenergic rather than dopamine stimulation may be more 
critical to maintaining anorexia following amphetamine (Samanin et al., 1978; 
Samanin and Garattini, 1982).
Microinjection of putative anorectic agents into specific brain regions 
have been used to locate neuroanatomical substrates for the control of feeding. 
Two brain regions in the lateral hypothalamus with differential activity on food 
intake have been isolated. In animals, injection of a-adrenergic agents, into the 
paraventricular area stimulates feeding (Leibowitz, 1978); while infusion of 
serotonin or fenfluramine into the same brain area attenuates feeding 
(Leibowitz and Papadakos, 1978). In contrast, infusion of dopamine and 
P-adrenergic agonists into the perifornical zone inhibits food intake (Leibowitz 
and Brown, 1980). Further, injection of amphetamine into the perifornical area 
reduces food intake (Leibowitz and Rossakis, 1979). In fixture, elaborations on 
this model will have to take into account our growing knowledge on the role of 
endorphins, peptides, and other neuromodulators such as GABA agonists 
(Blundell, 1981) and CCK (Gibbs et al., 1973; Kissileff et al., 1981) on feeding 
(for a discussion see Hoebel, 1984).
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Food deprivation studies have been widely used to investigate feeding 
behaviour and food intake in animals. In these experiments, the animal is 
allowed food for 1-2 hours, having been denied it for 16 to 48 hours. The 
amount of food consumed when access to food is granted represents the 
anorectic potential of the drug with which it had been pre-treated. There have, 
however, been five main reservations about the use of the food deprivation and 
traditional paradigms to test the anorectic potential of drugs. Firstly, severe 
fasting may itself be physiologically traumatic (Blundell and Latham, 1982) - 
thus, inferences drawn from this approach may be unlike feeding behaviour in 
non-deprived animals. Secondly, observations of feeding behaviour are made in 
deprived animals, and their neurochemistry is studied when they are satiated 
(Glick et al, 1973). Thirdly, solely measuring caloric intake is misleading as it 
provides no clue as to what component of the feeding process is impaired. 
Fourthly, consuming bland and novel laboratory foodstuffs within 
pre-determined time limits does not allow for the expression of certain eating 
behaviours in animals such as foraging and hoarding - thus, it has been 
suggested that examination of drug effects using ‘free-feeding’ paradigms and 
sequencing while continuously monitoring food selection may be more 
appropriate (Blundell, 1982). Fifthly, food deprivation is an unnaturalistic 
model of animal and even normal human consumatory behaviour whereby 
feeding periods are interspersed with non-feeding intervals (i.e. satiety 
produced by the food itself is also anorectic), and the opportunity of selection 
from a variety of foodstuffs of different macronutrient compositions, taste and 
texture is often afforded.
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It is now widely accepted that animals are able to discriminate and 
select their intake of macronutrients. For example, rats allowed access to fat, 
protein, carbohydrate, minerals, and water are able to maintain a balanced diet 
(Overmann, 1976). Voluntary self-selection is thought to be under the control 
of neurotransmitters. Amphetamines reduce carbohydrate and protein 
(McArthur and Blundell, 1983) and fat intake (Marks-Kaufinan and Kanek, 
1980) in non food deprived animals; paradoxically, both a small dose of 
amphetamine, 0.125 mg/Kg (Blundell and Latham, 1978) and lateral 
hypothalamectomy (Strieker and Zigmond, 1976) appear to increase food 
consumption in non-deprived rats. Amphetamines also have notable effects on 
feeding behaviour. When given to rats they eat quicker; additionally, pre­
treatment with the clonidine, an a-adrenergic agonist, will increase 
carbohydrate selection (Mauron et al, 1980). It appears that the main 
contribution of dopaminergic mechanisms to feeding might be to impair the 
regulation of sweet foods. For instance, selective D2 receptor and 
Diantagonists suppress sucrose intake in sham feeding in rats (Shneider et al., 
1986).
In humans, physiological doses of amphetamine (2.5 mg to 30 mg 
orally) has been shown to reduce appetite (with a peak atjabout 2 hours post 
drug) and, less strongly, caloric intake; additionally, initiation of eating might 
also be impaired (Silverstone and Stunkard, 1968). As in animals, the 
differential effects of noradrenaline and dopamine on feeding have been
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studied. In a preliminary study, thymoxamine (a noradrenergic blocking agent) 
attenuated the anorectic properties of subjects pre-treated with (/-amphetamine 
but spared its euphoriant effects; it was later shown that this mood 
enhancement could be attenuated by the selective D2 receptor antagonist, 
pimozide (Silverstone and Kyriakides, 1982). However, the effects of 
thymoxamine on amphetamine-induced anorexia was not replicated (Goodall et 
al., 1987). Importantly, in a recent study which compared the effects of d- and 
/-fenfluramine and (/-amphetamine on energy and macronutrient intake, it was 
shown that d-amphetamine alone produced a small but statistically insignificant 
decrease in sweet food intake; this reached statistical significance when 
(/-fenfluramine was given with (/-amphetamine. D-amphetamine (15 mg orally) 
also reduced feeding time and caloric intake (Goodall et al., 1992). It is worth 
noting that the overall percentage decrease following (/-amphetamine alone was 
considerable (15%), and may be biologically significant, and that a study with a 
larger number of subjects and less inter-subject variability might have been able 
to draw more definitive conclusions. Further studies using "temporal tracking’ 
of eating behaviour are needed, whereby hunger and desire or motivation to 
eat are examined at pre-determined stages of feeding. Dissociation between 
these parameters might indicate hunger per se may not control intake once 
feeding has been initiated.
In sum, in animals and humans, amphetamines have observable effects 
on the reduction of caloric intake and feeding time, and probably diminish 
sweet food intake and preference.
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5. The mesolimbic dopamine system and other important pathways 
in the reinforcement process: a theoretical framework for explaining 
the translation of motivation into behaviour
It has been hypothesised that the ‘limbic-motor interface’ (Mogenson et 
al, 1980; Heimer et al, 1982) is critical to the organization, direction, and 
maintenance of a co-ordinated response to changes in environmental 
conditions. Simply, biologically important changes in environmental conditions 
are carried as afferent stimulation, chiefly from the amygdala and hippocampus, 
to the ventral tegmental area (VTA). In the VTA, these afferent impulses are 
quantified and assessed (i.e. ‘gated’) by the nucleus accumbens (i.e. the 
‘interface’) which sends the efferent response to the motor system.
The neural connections between afferents to the AlO dopamine 
containing cells of the VTA and efferents from the nucleus accumbens is highly 
complex and imperfectly understood. The simplified schematic diagram of a rat 
brain (saggital section) below summarizes the essential elements and the 
principal neurotransmitter systems involved (Diagram. 3).
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Diagram. 3. Limbic afferents (yellow) to the nucleus accumbens are o f two functionally 
important types: (a) fibres from the central nucleus o f the amygdala (constituting the 
amygdala - ventral straitum - ventral pallidum axis) and (b) those from the hippocampus 
(Hippo). In addition, there are glutaminergic afferents from the dorsomedial thalamus 
(DMT) and the frontal cortex. Serotonergic afferents from the median and dorsal raphe 
bundles are not shown. Further, there is noradrenergic afferent innervation o f the nucleus 
accumbens by the locus coeruleus (LC). It has been suggested that the serotonergic and 
noradrenergic innervation provide non specific arousal o f the AW  dopamine containing 
cells o f the VTA. However, regulation o f AlO neurones by 5-HT shows evidence offunctional 
heterogeneity. For instance, while both dorsal and median raphe bundles attenuate firing o f 
AID cells, median raphe fibres also stimulate dopamine containing cells from the VTA to the 
prefrontal cortex (Hervé et al, 1981); hence, this inhibition o f dopamine may be mediated by 
5-HT2 fibres (Ugedo et al, 1989). Interestingly, injection o f 5-HT into the VTA increases 
dopamine release (Guan and McBride, 1989). 5-HT^ receptor antagonists inhibit this 
release (Costall et al., 1987) and attenuate firing o f both A9 and A 10 dopamine containing 
cells (Sorensen et al., 1989). In addition to the usual ‘pacemaker’ or background activity, 
AlO dopamine neurones are capable o f ‘burstfiring’ in specific VTA areas to direct and co­
ordinate the response to the stimulus and activate the cognitive processes necessary to deal 
with it (D’Angio et al., 1988). The mechanism by which the nucleus accumbens gates imput 
from the amygdala and hippocampus appears to be controlled by noradrenaline-doparnine
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interactions. Stimulation o f fi-receptors innervated by the LC checks the imput o f  
hippocampal information into the VTA, an effect which is blocked by fi but not a-receptor 
antagonists (Unemoto et al, 1985a and b). This ‘gating’ mechanism is indirect and 
additional to the direct ‘gating ’ mechanism o f hippocampal imput by the action o f dopamine 
itself on receptors. Thus, noradrenergic activation closes the hippocampal ‘gate’ by 
indirect stimulation ^-receptors and enhancement o f  D j  neurotransmission; conversely, 
inhibiting preceptors and receptors open the hippocampal ‘gate ’. The amygdala is a 
main processor o f sensory and affective imput in the brain and relays information from 
cortical association areas to the VTA via the lateral hypothalamus. These projections may 
utilize somatostatin, neurotensin, or both. Though a-noradrenergic receptors are not 
involved with the activity o f the hippocampal ‘gate ’, there is evidence to suggest it has 
important interactions with a specific dopamine receptor subtype, the receptor, in 
regulating the amygdaloid gate (Cools and Van Rossum, 1980; Cools, 1986). Thus, a- 
receptor antagonists close the amygdaloid ‘gate ’ and suppress dopamine induced 
hyperactivity by systemic d-amphetamine. Notably, the effect o f closing the amygdaloid gate 
and opening the hippocampal gate are functionally similar across a wide range o f  
behaviours. Importantly, however, /3-receptor antagonists, which open the hippocampal gate, 
only block d-amphetamine-induced hyperactivity when given before but not ajier 
d-amphetamine. This may explain why receptor antagonists inhibit the acquisition o f  
incentive motivational learning but does not suppress its maintenance once established 
(Beninger, 1983). An open amygdaloid ‘gate’ is, therefore, essential for incentive 
motivational learning. This noradrenergic-dopamine coupling (the 'seesaw ’ hypothesis) has 
been used to explain other important phenomena. For instance, in the stressed animal or 
with the presentation o f  a novel environment or stimulus, the ‘seesaw ’ 11 state is achieved - 
the amygdaloid gate is open (and the hippocampal gate closed), there is high noradrenaline 
release, and incentive motivational learning is maximal; in contrast, the well habituated 
animal is in ‘seesaw ’ state type I  - an open hippocampal (but closed amygdaloid) gate, there 
is little or no noradrenaline release, and maintenance o f  responding is favoured. Nicotinic 
cholinergic afferents from the dorsolateral tegmental nucleus and the ventral parabrachial 
nucleus may also activate AlO cells (Gould et al, 1989). Peptides (e.g. enkepahalins) and 
other neuromodulators such substance P may be important in regulating stress-induced VTA 
activation. The various opioids are indirect stimulants o f dopamine and each has a specific
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mechanism o f activation by acting on separate groups o f neurones; at low doses, enkephalin 
injection onto the VTA enhances conditioned place preference and self-administration 
(Kelley et al, 1989).
The first-order efferents from the nucleus accumbens (orange) are GABA containing 
neurones whose innervation includes the VTA, lateral habenula (LH), and the ventral 
pallidum (VP). GABA stimulation o f different regions o f the VTA produces behaviourally 
distinct responses. For example, while GABAergic stimulation o f the anterior VTA leads to 
sedation and GABA antagonism at the same site locomotion; stimulation o f  the caudal VTA 
produces locomotion, aggression, and feeding in satiated rats (Arnt and Scheel-Kruger, 
1979; Stinus et al., 1982). The mechanism by which specific behaviours are selected in 
response to ‘gated' stimuli from the VTA-nucleus accumbens axis remains poorly 
understood. The ventral pallidum is a critical output pathway as lesioning it with ibotenic 
acid blocks amphetamine-induced locomotion (Swerdlow et al, 1986) and the reinforcing 
effects o f  cocaine and heroin (Hubner and Koob, 1990). The habenula may be involved with 
integrating the outputs o f the dorsal and ventral straitum (Thornton et al, 1987) by serving 
as a relay centre from the basal ganglia and other limbic areas to the VTA.
The other landmarks in the diagram are: C-P (Caudate-putamen), AC (anterior commisure, 
SNr (Substantia Nigra); PAG (Periacqueductal grey), OT (olfactory tract), and Cer 
(cerebellum). GABAy  ^ receptor complexes are coloured pale blue. Dopaminergic fibres 
running from the VTA to the nucleus accumbens are shown in red.
The diagram is by courtesy o f  George Koob (1992) and Elsevier Science Publishers Ltd.
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6, Pharmacology of 5-HTg receptors
6.1. Discovery, identification, and nature of the 5-HT] receptor
In studies on the sympathetic control of the cardiovascular system, 
Fozard and colleagues (Fozard & Mwaluko, 1976; Fozard & Mobarok-Ali, 
1978) found that 5-HT induced noradrenaline release which was attenuated by 
(-) cocaine at non-5HT%/5-HT2 sites but not by methysergide. This suggested 
the presence of a novel subtype of 5-HT receptor, now known as the 5-HT] 
receptor. Classically, responses mediated by the 5-HT] receptor are: (a) 
unaffected by ketanserin (a selective 5-HT2 blocker), methysergide (a 
non-selective 5-HT% and possibly 5-HT2 antagonist), and methiothepin (a 
non-specific 5-HTi, 5-HT2 and perhaps 5-HTiD antagonist); (b) stimulated by 
2-methyl-5-HT, a 5-HT] agonist; (c) selectively attenuated by (-) cocaine and 
synthesized 5-HT] receptor antagonists such as MDL 72222 or ICS 205-930 
(Bradley et al., 1986).
Peripherally, 5-HT] receptors are primarily located in the autonomic 
nervous system (Wallis, 1981; Fozard, 1984) where they may be involved in 
the modulation of inflammatory pain (Richardson et al., 1985). Both ligand 
binding (Kilpatrick et al., 1987; Watling, et al., 1988) and autoradiographic 
studies (Hoyer et al., 1989) show a wide distribution of 5-HT] receptors in the 
central nervous system. The highest concentrations are in the nucleus tractus 
solitarius (Pratt et al., 1989), the sensory processing areas of the spinal cord
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(dorsal horn), the nuclei of the vagus and trigeminal nerves, the area postrema 
and the limbic system (Kilpatrick et al., 1987 and 1989; Higgins et al., 1989; 
Barnes et al., 1990a).
The 5-HT] receptor is a ligand gated ion channel. 5-HT] receptor 
activation either peripherally or centrally leads to a depolarization, whereby 
membrane conductance to sodium and potassium is increased. Studies of 
NG108-15 (Yakel et al., 1990) and N18 cells (Yang, 1990) show that the 
cations are differentially permeable to the membrane (according to size), 
suggesting a water-filled pore with an approximate diameter of 0.75 nm); in 
contrast, the membrane is relatively impervious to anions (Yang et al., 1992). 
Interestingly, 5-HT] receptors have been cloned from NCB-20 neuroblastoma 
cells expressed in Xenopus oocytes (Maricq et al; 1991) which implies that the 
principal component of the channel is contained within a single subunit.
6.2. Impact of 5-HT] receptors antagonists 
on normal human behaviour
In preliminary investigations, Orwin and Fozard (1986) found that 
systemic injection of 0.3 mg/kg of MDL 72222, a selective 5-HT] receptor 
antagonist, inhibited the flare response produced by intradermal injection of 
5-HT; additionally, the personal experience of Fozard who participated in the 
study was that ‘Substantial blockade of peripheral 5-HT] receptors does not 
result in overt (behavioural) pharmacological activity” (Fozard, 1989). The
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more compelling evidence is, however, that for the last few years 5-HTg 
receptor antagonists have been in widespread use world-wide for the treatment 
of post-operative nausea and vomiting, and emesis induced by chemotherapy. 
To date, there have been no reports of significant effects on normal human 
behaviour. This is consistent with the finding that 5-HT] antagonists have no 
discernible effects on normal animal behaviour (Costall et al., 1990).
6.3. Modification of brain dopamine function by 5-HT] 
receptors antagonists
The role of 5-HT in the moderation of mesolimbic activity though 
intensively investigated remains imperfectly understood. Before the advent of 
5-HT] receptor antagonists, microinjection of 5-HT into the nucleus 
accumbens was shown to block dopamine or amphetamine-induced 
hyperactivity (Costall et al., 1976; Pycock et al., 1978; Jones et al., 1981). 
Chemical lesions of 5-HT fibres in the nucleus accumbens by 5,7 
dihydroxytryptamine leads to a rise in both spontaneous and 
amphetamine-induced hyperactivity (Carter and Pycock, 1979; Lyness and 
Moore, 1981), and ablation of the median raphe nucleus increases dopamine- 
induced hyperactivity (Costall et al., 1976). It was therefore postulated, quite 
simply, that 5-HT exerted inhibitory control on dopaminergic function, and that 
drugs which antagonized 5-HT would facilitate locomotion. However, it soon 
became clear that such a simple explanation of 5-HT/dopamine interactions 
could not be supported. For instance, administration of drugs with varying
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degrees of antagonism at 5-HT% and 5-HT2 receptors (e.g. methysergide, 
cyproheptadine, metorgiline, and ritanserin) were shown to have little effect on 
locomotor activity at physiological doses and to impair motion only at high, 
and possibly non-specific, doses (Costall et al., 1988). In addition, the impact 
of injecting 5-HT into the nucleus accumbens on spontaneous locomotor 
activity remains variable: ineffectiveness, enhancement, and reduction have all 
been reported (Jackson et al., 1975; Pijenenburg et al., 1975; Costall et al., 
1979; Makunjuola et al., 1980). It was, therefore, evident that 5-HT control of 
mesolimbic dopamine function was complex (as there was evidence for both 
facilitation and inhibition), and that important missing links confounded our 
understanding. Recently, the landmark discovery of a new subtype of 5-HT 
receptor (the 5-HT] receptor) has been of considerable scientific interest as it 
promises to be one of the essential clues to elucidating the nature of central 
5-HT/dopamine interactions.
In a series of classical experiments, the ability of 5-HT] receptor 
antagonists to oppose mesolimbic dopaminergic activity has been demonstrated 
using three paradigms. Firstly, hyperactivity induced by the injection of 
dopamine into the nucleus accumbens or ventral tegmental area (VTA) of the 
rat or marmoset was blocked by the 5-HT] receptor antagonist GR 38032F, 
ondansetron (Costall et al., 1987). This blockade was comparatively greater 
than that achieved by the D2 receptor blocker, fluphenazine. In addition, 
fluphenazine, unlike ondansetron, reduced activity to below baseline levels and 
lead to "rebound’ hyperactivity when it was withdrawn (Costall et al., 1988).
48
Also, unilateral injection of dopamine infusion into amygdala stimulates 
hyperactivity (Bradbury et al., 1985) which can be attenuated by ondansetron 
or fluphenazine given either peripherally or injected into the same or 
contralateral side as the dopamine infusion (Costall et al, 1987). This suggests 
a role for the amygdala in the regulation of dopamine-induced hyperactivity and 
of 5-HT on inter-hemispheric control of limbic activity. Curiously, at high 
doses (100 pg/kg to 1000 pg/kg i.p. and bd.) the ability of the 5-HTg receptor 
antagonists ondansetron and ICS205-930 to antagonize dopamine-induced 
hyperactivity is lost (Costall et al, 1990). While there is, at present, no 
satisfactory explanation for this non-linear dose response pattern, it is 
important to note that this property is not shared by the newly developed 
selective 5-HT] receptor antagonist, GR 68775C (Costall and Naylor, 1992).
In the second model, acute micro-injection of amphetamine (which 
causes the release of endogenous dopamine) into the nucleus accumbens of the 
rat leads to hyperactivity which is blocked by peripheral administration or 
infusion of ondansetron into the nucleus accumbens (Butler et al, 1988). 
Amphetamine-induced hyperactivity is facilitated by administration of 
2-methyl-5-HT (Costall et al, 1987). Interestingly, the 5-HT] antagonist, 
ondansetron, has been shown to block CPP to amphetamine (Van der Hoek et 
al, 1989), and MDL 72222 attenuates CPP to the amphetamine-like substance, 
MDMA (Bilsky and Reid, 1991); in gainsay, Carboni et al (1989) were unable 
to obtain a similar effect using a similar dose (0.03 mg/kg) of two other 5-HTg 
antagonists, tropisetron and MDL 72222 (Diagram 4). The present thesis
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includes the first investigation of the effect of 5-HTg receptor blockade (using 
GR 38032F and GR 68775C) on amphetamine-induced behaviour in humans.
Diasram 4
INHIBITION OF CONDITIONED PLACE PREFERENCE 
BY 5-HT3 RECEPTOR ANTAGONISTS
Attenuation
Drug of Abuse 5 -HT3 Antagonist of CPP? Reference
Morphine Tropisetron (0.03 mg/kg) Yes Cartxini et ai, 1988
MDL 72222 (0.03 mg/kg) Yes Cartx)ni et ai, 1988
Ondansetron (0.01 mg/kg) Yes Higgins et al, 1992
Nicotine Tropisetron (0.03 mg/kg) Yes Cartx)ni et ai, 1988
MDL 72222 (0.03 mg/kg) Yes Cartx)ni et al, 1988
Amphetamine Tropisetron (0.03 mg/kg) No Caitoni et al, 1988
MDL 72222 (0.03 mg/kg) No Cartx)ni et ai, 1988
Ondansetron (0.03 mg/kg) Yes Van der Hoek et al.
MDMA MDL 72222 (0.03 mg/kg) Yes Bilsky & Reid, 1991
In the third paradigm, locomotor hyperactivity induced by injection of 
3 pg per side of the neurokinin agonist DiMe-C7 (which increases endogenous 
dopamine turnover {Eison et al., 1982}) into the VTA was attenuated by 
administration of 100 pg/kg sc. of GR 38032F (Hagan et al., 1987 and 1990).
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Interestingly, there is further evidence from in vivo studies that the 
5-HT3 receptor is intimately involved in the regulation of central dopamine 
release. For instance, intraventricular injection of the potent S-HT3 receptor 
agonists, 2-methyl-5-HT and 1-phenylbiguanide, into the nucleus accumbens of 
anaesthetised rats produces a dose-dependent increase in dopamine release 
(Jiang et al, 1990; Chen et al, 1991); also, the 5-HT3 receptor antagonists, 
zaco|HKte and ondansetron inhibit 1-phenylbtguanide-induced hyperactivity and 
decrease 3,4-dihydrophenylacetic acid (DOPAC) and homovanillic acid (HVA) 
levels when injected into freely moving rats (Chen et al, 1991).
6.4. S-HT^/dopamine interactions on alcohol-induced behaviour
From electrophysiological studies, the acute exposure to a small dose of 
ethanol increases 5-HT neurotransmission at excitatory 5-HT3 receptors which 
facilitates central dopamine release {Diagram 5} (Lovinger and White, 1991). 
There are also excitatory effects at the nicotinic acetylcholine receptor, and 
activation of 5-HT3 receptors stimulates the release of other neurotransmitters 
such as acetylcholine (Barnes et al., 1989), CCK (Paudice and Raiteri, 1991), 
noradrenaline, and GAB A (Ropert and Guy, 1991). With intoxication, there is 
reduced neurotransmission at most excitatory receptors. Notably, there is 
inhibition of glutamate transmission at kainate and NMDA receptors, and impairment of
voltage-sensitive Ca '^*' channels; in contrast, there is increased activity at the
inhibitory neurotransmitter^ GABA^ Dependence on ethanol causes
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upregulation of NMDA and voltage sensitive Ca^ "*” channels and down 
regulation of GABA^.
Diasram 5
1 5-HT 2 5-HT 
50 mM EtOH
3  5-HT
^  V
150 pA
B 80-1
Ethanol (mM)
10 sec
Ethanol (EtOH) potentiation of the amplitude of 5-HT-activated current.
By courtesy o f  Lovinger and White (1991) and Neuroscience Letters.
It has been suggested that 5-HTg receptor activation modulates the 
reinforcing properties of alcohol by enhancing the release of dopamine 
(Blandina et al., 1988; Yoshimoto et al., 1992). Correspondingly, 5-HTg 
antagonists inhibit alcohol-induced dopamine release in the nucleus accumbens 
(Carboni et al., 1989; Costall et al., 1990; Wozniak et al., 1990), and decrease
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alcohol consumption in a free-choice paradigm in rats (Sellers et al., 1988; 
Fadda et al., 1991; Knapp and Pohorecky, 1992). The ability of alcohol to act 
as a discriminative cue is attenuated by 5-HTg receptor blockade in pigeons 
(Grant and Barett, 1991) {diagram 6}. Importantly, environmental cues are 
also crucial to conditioning ethanol drinking behaviour and are powerful 
enough to evoke alcohol-seeking behaviour in the absence of alcohol (Samson 
and Li 1988a; Samson et al., 1988b; Samson and Grant, 1990). In addition, the 
intensity of the motivation to drink in humans is enhanced in the presence of 
the cue. If 5-HTg blockade can be shown to have a similar effect in humans, as 
in animals, it may open up new avenues for the treatment of alcohol abuse, and 
possibly of other addictive behaviours (Tricklebank, 1989).
Diasram 6
THE EFFECT OF S-HTg RECEPTOR ANTAGONISTS 
ON ETHANOL CONSUMPTION/DISCRIMINATION - 
ANIMAL STUDIES
Test Species 5 -HT3 Antagonist Attenuation ? Reference
Free choice In Marmoset Ondansetron Yes Oakley et al, 1988
ethanol-preferring (0.01 mg/kg bd)
animals Rat Ondansetron Yes Sellers et al, 1992
(0.1 mg/kg bd)
Rat Zacopride Yes Knapp & Pohorecky,
(5, 10 mg/kg bd) 1992
Rat (SP) MDL 72222 Yes Fadda et al, 1991
(3-7 mg/kg bd)
Drug Pigeon Tropisetron Yes Grant & Barrett,
discrimination (0.1-0.56 mg/kg) 1991
MDL 72222 Yes Grant & Barrett,
(3-17 mg/kg bd) 1991
Zacopride Yes Grant & Barrett,
(0.56-1.7 mg/kg) 1991
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6.5. Impact of 5-HT3 receptor blockade on cognitive performance
Early experiments in rats have shown that the 5-HTg receptor 
antagonists, ondansetron and zacopride, can reverse scopolamine-induced 
deficits on the T-maze reinforced alternation task. Performance was, however, 
not improved in untreated rats (Barnes et al., 1990b). This reversal was 
attributed to facilitation of cholinergic transmission. Though 5-HT3 receptors 
may mediate the release of acetylcholine in cortical tissue (Barnes et al., 1989), 
5-HT] receptor antagonists, probably, only optimise cholinergic activity in 
undamaged neurones as they do not reverse the cognitive deficits produced by 
hemicholinium-3 lesions (Coughlan et al., 1991). Similar results have been 
obtained in the marmoset where ondansetron caused a dose-dependent 
decrease in the number of attempts to criteria in the object discrimination and 
reversal learning tasks (Domeney et al., 1991). From a preliminary study in 
humans, there is evidence to suggest that dosages between 0.25 mg and 1 mg 
bd. of ondansetron can improve performance in healthy 50 year olds with 
age-associated memory impairment on computerized tests of recall, new 
learning and reasoning (Crook and Larkin, 1991). Interestingly, 5-HTg 
antagonists do not correct benzodiazepine-induced impairment which suggests 
that neuronal pathways other than 5-HT3-cholinergic interactions may mediate 
this effect.
54
6.6. 5-HT3, and the effects of 5-HT3 receptor antagonists on caloric 
and macronutrient intake following amphetamine
There is considerable evidence the 5-HT pathways in animals and 
humans are intimately involved in the regulation of feeding. Briefly, in animals, 
drugs which increase serotonin neurotransmission produce anorexia by: (a) 
increasing the availability of the 5-HT precursor, tryptophan (Latham and 
Blundell, 1979); (b) facilitating 5-HT release from nerve terminals 
{e.g. fenfluramine} (Samanin et al., 1980); (c) enhancing 5-HT activity such as 
quipazine and m-chlorophenylpiperazine, MCPP (Garattini, 1978) and (d) the 
administration of 5-HT itself to ‘free-feeding’ rats (Blundell and Latham, 1979) 
or rats with ventral medial hypothalamic (VMH) lesions (Bray and York, 
1972). Further, the anorectic effects of fenfluramine can be reversed by 5-HT 
receptor blockade (Blundell and Latham, 1980), and the selective 5-HT 
re-uptake blockers, sertraline and fluoxetine, reduce food intake (Lucki et al., 
1988; Clifton et al., 1989 respectively). Serotonergic mechanism also influence 
macronutrient intake. In particular, protein intake appears to be regulated by 
the balance between tryptophan and neutral amino acids (Anderson, 1979). In 
Wenling rats receiving fenfluramine or fluoxetine, both of which increase 
serotonin neurotransmission, the relative amount of protein ingested increased 
while total caloric and carbohydrate intake decreased (Wurtman and Wurtman, 
1977 and 1979); conversely, serotonin depletion by intravenous p-chloro- 
phenylalanine or intraventricular 5,7-dihydroxytryptamine leads to a reduction 
in protein consumption. In addition, d-fenfluramine in both obese and normal
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weight humans reduces caloric, carbohydrate and fat intake while sparing 
protein consumption {(Wurtman, 1981; Wurtman et al., 1982; Wurtman et al., 
1985, McGuirk et al., 1991) and (Goodall et al., 1992)}. There are, however, 
some less definitive results on normal weight subjects (Blundell and Rodgers, 
1980; Hill and Blundell, 1986).
While experiments using relatively specific agonists and antagonists at 
5-HT receptors have implicated various subtypes of 5-HT \ and 5-HT2 in the 
regulation of feeding, the evidence for a central role for 5-HTg receptors 
requires further investigation. While some studies in rats have failed to 
demonstrate an effect on caloric intake in ‘free-feeding rats’ (Hutson et al, 
1988; Kennett and Curzon, 1988; Dourish et al, 1989; Neill and Cooper, 
1989); in contrast, others have shown a small reduction in feeding time over a 
narrow range of dosages (Van der Hoek and Cooper, 1990a; Fletcher and 
Davies, 1990). The findings of 5-HT agonists on feeding are hard to interpret. 
For examples, the 5-HT3 agonists, 1,3 phenylbiguanide and 2-methyl-5-HT, 
decreased food intake when given i.p.(Kennett and Grewal, 1992; Simansky et 
al, 1991). This effect was not inhibited by 5-HTg receptor antagonists and 
may, therefore, be mediated by non 5-HTg mechanisms. Curiously, 
2-methyl-5-HT was without effect when administered i.c.v. (Simansky et al,
1991). To date, there has only been one experiment on the effects of the 
5-HT3 receptor antagonist, ondansetron, on amphetamine-induced anorexia. 
This study found ondansetron increased sweetened mesh intake at certain 
dosages (30 pg and 100 pg) while reducing sucrose ingestion at 10 pg and 30
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pg. Ondansetron also augmented the anorectic effects of amphetamine (Cooper 
et al., 1993). These results are hard to interpret because: (a) the size of the 
effect is small and may not be biologically relevant (although it is statistically 
significant), and (b) the direction of change is contradictory between the two 
paradigms. If these results are replicated and proven to be germane it does raise 
certain intriguing possibilities. These include: (i) amphetamine-induced anorexia 
is, at least in part, mediated by the facilitation of serotonergic transmission; (ii) 
ondansetron somehow regulates the on/off switch for the expression of 
anorexia, perhaps via cognitive processes; and (iii) ondansetron may, under 
certain conditions, enhance dopaminergic neurotransmission. The present thesis 
includes the first study of the 5-HTg receptor antagonist, GR 68775, on the 
anorectic properties of amphetamine in humans.
7. Objectives of the thesis
The present thesis contains the first laboratory experiments in
humans designed to assess the impact of 5-HT] receptor blockade on the 
subjective and behavioural effects of alcohol and amphetamine. I have chosen 
to study these particular drugs of abuse because alcohol facilitates dopamine 
neurotransmission indirectly by increased 5-HT activity at 5-HTg receptors, 
and amphetamine causes the direct release of dopamine from nerve terminals. 
My hypothesis is that in humans, like animals, 5-HTg receptor blockade will 
attenuate dopamine-mediated subjective positive effects and behaviours 
induced by administration of these drugs of abuse. Specifically, I shall
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investigate the effects of 5-HTg receptor blockade on subjective positive mood 
induced by alcohol and amphetamine. I shall also investigate whether the 
effects of 5-HT] receptor blockade on amphetamine-induced changes in 
cognitive performance, and caloric and macronutrient intake are inhibitory or 
enhancing.
8. Some practical considerations in the adaptation of animal 
studies into the design of human experiments
From animal studies, it is clear that both alcohol and amphetamine 
exert their rewarding effects via a range of neurobiological pathways and 
transmitters. Priming is a function of general central nervous system (CNS) 
stimulation. Reinforcement involves a complex interplay of both 
neurobiological and environmental systems. Key features of the reinforcement 
process such as increased hedonic tone, preference, and particularly for alcohol 
- the relief of anxiety - which at first sight appear to be mediated by diverse 
variety of neurobiological pathways, and environmental pressures such as 
experience and exposure, are thought to be expressed via a common final 
neuronal pathway mediated by dopamine* Diagram 7 below shows the 
contributions nature and nurture to the expression of alcohol-induced 
motivation and reinforcement.
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Diagram 7: shows the contributions o f the neurochemical pathways that 
mediate the impact o f both biological and environmental cues on 
reinforcement, priming, and motivation following acute alcohol intake.
Anxiolysis 
GABA 
? EAA. 
Preference 
5-HT., DA_______
Hedonic tone 
DA., ? End.CNS stimulation DA,NA, 7 End.,
? Ach., ? EAA
Biological I
Genetic factors Environmental cues
Pharmacological and
Reinforcement
Modulators
Non Biological
Priming and 
motivation
Alcohol-induced reward
behavioural history
Key: Dopamine (DA), endorphins (End), acetylcholine (Ach), excitatory 
amino acids (EAA), noradrenaline (NA), gamma-aminobutyric acid (GABA), 
serotonin (5-HT).
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In humans, it is difficult to use operational measurements, as in animals, 
to quantify the reinforcing value of a drug of abuse. Hedonic tone is an 
important (Engel, 1977; Solomon, 1974; Stolerman, 1992), but not exclusive 
(Wise and Bozarth, 1987), facet of reinforcement since many drugs of abuse 
are dysphoric on first presentation yet self-administration can eventually occur. 
In animals, it has been suggested that positive hedonic tone increases the 
strength of reinforcement and sensitivity to the effects of the reinforcer. 
Anhedonia has the opposite consequence (Solomon and Corbitt, 1974; Carr et 
al., 1989; Stolerman, 1992; Willner et al., 1992). Chronic Mild Stress (CMS) 
has been shown to be a workable animal model of anhedonia which reduces the 
sensitivity of reinforcement. Trained animals after two weeks of CMS showed 
less preference for environments associated with one of the following 
reinforcers - 0.7% and 3.4% sucrose, food pellets, amphetamine (0.5-1.0 
mg/kg), or morphine (0.7 mg/kg) - than non stressed animals. In addition, 
animals exposed to CMS show reduced sensitivity to the reinforcing effects of 
the D2/D3 agonist quinpirole (Willner et al., 1992). This appears to be 
homologous to the Solomon and Corbitt’s (1974) model of hedonic tone and 
drug administration in humans. They suggested that in non dependent 
individuals, positive subjective well being (including hedonic tone), which may 
include pleasure, is directly related to the strength of the desire or urge to 
self-administer the reinforcer. In humans, the positive subjective effects on 
mood of reinforcers can be readily measured by standardized rating scales such 
as the Profile of Mood States questionnaire, POMS (McNair et al., 1971), or 
by simple visual analogue scales (VAS) such as the Bond-Lader Scale (Bond
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and Lader, 1974) which are easier to use and sensitive to drug effects; 
however, VAS may be more prone to variability in the ratings.
In addition, I have adopted some of the lessons on conditioning from 
CPP in animals into my experiments in humans. In this paradigm, 
familiarization, whereby animals are pre-exposed to the test environment and 
conditions, is an important prerequisite as it reduces novelty. Similarly, in my 
experiments, subjects are familiarized with the test room and experiment 
measures the day before the onset of testing. The time spent during the 
familiarization is limited to about half of that for the test paradigm. This is 
because excessive exposure without the presentation of the reinforcer may lead 
to latent inhibition, whereby the difficulty of achieving conditioning is 
increased. It is confirmed that subjects understand the adjectival description of 
the variables on the VAS and are allowed to practice. Subjects are also trained 
until they reach ‘ceiling’ scores on the computerized psychomotor tasks.
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EXPERIMENT 1 
Hypotheses and objectives
Like other drugs of abuse, alcohol possesses reinforcing properties 
which are critical to directing, controlling, and sustaining drug-seeking 
behaviour (Stolerman, 1992). Animal experiments suggest that dopaminergic 
pathways running from the ventral tegmental area to the nucleus accumbens 
play a crucial role in mediating the reinforcing effects of drugs of abuse 
(Imperato and Di Chiara 1986; Wise and Bozarth, 1987, Koob, 1992). Thus, 
acute administration of alcohol increases extracellular levels of dopamine in the 
nucleus accumbens (Gessa et al., 1985; Koob, 1992), and dopamine receptor 
antagonists decrease alcohol consumption in a number of behavioural 
paradigms (Samson et al., 1988). A recently described subtype of 5-HT 
receptor, the 5-HT] receptor, appears to modulate the effect of alcohol on 
dopamine-mediated reinforcement processes. For example, in rodents, 5-HTg 
receptor antagonists inhibit alcohol-induced dopamine release in the nucleus 
accumbens (Carboni et al, 1989; Costall et al, 1990; Wozniak et al., 1990). 
Also, in vitro studies show that alcohol potentiates the ability of 5-HTg 
receptors to increase cation conductance (Lovinger and White, 1991). In 
humans, it is difficult to quantify the reinforcing value of a drug of abuse 
directly. It is, however, generally accepted that reinforcement can be measured 
indirectly since it is related, though not exclusively dependent, on its ability to 
produce positive subjective effects (Wise and Bozarth, 1987; Stolerman, 1992) 
which are more readily assessed.
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It has been suggested that 5-HTg antagonists may improve cognitive 
deficits induced by scopolamine in the T-maze reinforced alternation task in 
rats (Barnes, 1990b) and the marmoset (1991), presumably by facilitation of 
cholinergic neurotransmission (Barnes, 1990a). A preliminary study in humans 
found improvements in age-associated memory impairment and on 
computerized tests of recall, new learning, and reasoning following 
ondansetron treatment (Crook and Larkin, 1991). To date, there has been no 
study of S-HTg/alcohol interactions on cognitive performance.
My objectives are to investigate whether the 5-HTg antagonist, 
ondansetron: (a) decreases the positive subjective effects of alcohol, and hence, 
its reinforcing value; and (b) improves cognitive performance in a computerized 
task, or reverses alcohol-induced deficits.
Method
Subjects
Sixteen healthy male volunteers between the ages of 19 and 49 years 
(mean age 32.8 years) who were social drinkers (mean ± s.e.m alcohol intake in 
units/week 10.8 ± 1.6) were studied. One unit of alcohol as defined by the 
Royal College of Physicians (1987) is a standard, single, public house measure 
of alcohol (e.g. a pint of lager, beer or normal strength cider, one glass of
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wine, or one single measure, 1/6 of a gill, of a spirit such as whisky or gin). 
Subjects were recruited from individuals who had shown a willingness in the 
past to be involved in psychopharmacological studies. Each subject received a 
psychiatric interview, to exclude a history of mental illness or substance misuse, 
and was examined medically to confirm they were in good health. Subjects 
consented in writing to participate in the study. Written consent was also 
obtained from their family doctors. Permission to conduct this investigation 
was granted by the Oxford District Psychiatric Research Ethics Committee.
Laboratory
The study was carried out at the MRC Psychopharmacology Unit in a 
testing room approximately 10 feet x 12 feet in size. In one comer of the room 
there was a desk and chair, and above it, a video camera and recording 
equipment. Output from the camera was displayed on a monitor in the 
nurses’observation station two rooms away. Subjects were informed they were 
being observed by the camera as a safety precaution and to monitor 
completion of the experimental measures. Subjects knew the session was not 
being recorded on videotape. An easy sofa chair was placed in front of a Viglen 
486 DX computer which was connected to a printer, and a clock was sited on 
the window sill. Subjects were instmcted to sit where they liked and allowed 
to roam freely in the room. Also, they kept their own time for the periodic 
measurements during the experiment. The testing room contained fictional 
material and magazines which subjects were allowed to read. Communication
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between subjects and the experimenter was restricted to the time of dosing, 
setting up the computer, and presentation and measurements of breath alcohol 
as described in the design.
Visual Analogue Scales (VAS)
Subjects rated their subjective feelings at specified time points (the 
details are given below) on ten VAS items by placing a mark on a 100 mm line 
anchored with the endpoints of ‘Not at all’ on the left hand side and 
‘Extremely’on the right. VAS were scored for each time point by measuring 
the distance between the left hand side endpoint and the subject’s mark. The 
following six adjectival variables were derived from descriptions of factor 
scores on the Profile o f Mood States [POMS] (McNair et al, 1971): 
^"energetic'', Relaxed*’, “agreeable*', “cheerful*’, “confident**, and “clear­
headed**', the rest ('content**, “optimistic**, “feel good**, and “desire for a 
drink**) were chosen on the basis of a previous open study on the subjective 
effects of alcohol (see appendix la for a sample of the VAS). POMS variables 
were chosen because this scale has been shown to be a reliable measure of the 
mood-inducing effects of psychoactive drugs (Lorr et al., 1962; Mirin et al., 
1971) including alcohol (Nathan et al., 1970a and b). The presentation of mood 
measures as VAS has been shown to be sensitive to psychostimulant effects 
(Chait and Johanson, 1988; Fischman et al., 1990).
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Computerized Simple Reaction Time (SRT)
The SRT is a well known and validated computerized tests for assessing 
the effects of psychoactive drugs on cognitive performance and motor function 
(for reviews see Fleishman, 1964; Hindmarsh, 1980; Janke, 1980; Smiley, 
1987; Curran, 1988; Spiegel, 1989). In the SRT, the subject is shown an empty 
box in the centre of a computer screen as a warning stimulus. After a random 
delay of between 1 and 10 seconds, a target square is displayed within the box. 
The subject is required to respond to the display of the target box as quickly as 
possible by pressing the space bar. No control files are used as the random 
timing is generated internally. In this experiment, the SRT was configured to 
run for 3 minutes.
Design
Sixteen subjects received each of the following four treatments in a 
double-blind, randomized, Latin square design: (a) alcohol (580 ml of 3.6% 
alcohol content by volume of lager) + placebo ondansetron; (b) placebo alcohol 
(580 ml of alcohol-ffee lager) + placebo ondansetron; (c) placebo alcohol + 
ondansetron (4 mg) and (d) alcohol and ondansetron. There was a 4-7 day 
interval between treatments. Prior to testing, all subjects were familiarized with 
the test room conditions, and trained in the use of VAS as described 
previously. Possible differences in taste between the lager and alcohol-free 
lager were disguised by chilling and the addition of 20 ml of lime. The
66
effectiveness of this masking had been confirmed beforehand in a previous open 
study.
Subjects were studied after a 4 hour fast at 1400 hours when they 
received ondansetron or matching placebo. The drink of alcohol or placebo 
alcohol was given 60 minutes later. Breath alcohol concentration was measured 
20 minutes following the drink with a Lion SD-2 alcometer (breathalyser). 
VAS on 100 mm lines were completed 20 and 10 minutes before ondansetron 
and then 3, 5, 10, 15, 20, 20, 35 minutes after the drink. Subjects were not 
allowed to refer to previously completed VAS. The SRT was carried just 
before the drink and after the last VAS.
Data analysis
The VAS rated 20 min. before ondansetron were used as baselines, and 
subsequent scores were subtracted from them. Subjects were categorized 
according to four groups: placebo and placebo, ondansetron and placebo 
alcohol, alcohol and placebo ondansetron, and alcohol and ondansetron. A 
three-way (for alcohol x ondansetron x time) repeated measures analysis of 
variance (ANOVA) was performed (table I). The mean of the change in the 
VAS scores from baseline was determined. Confidence intervals were derived 
for the difference in score between the groups; however, to minimize type I 
errors only those VAS variables on which there was a significant alcohol x 
ondansetron x time interaction at the 5% level from the ANOVA were
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subjected to inter-group post-hoc paired t-tests (table II). Fig. I shows the 
change in mean scores from baseline were plotted against time for the 
following VAS all of which had significant interactions (at the 5% level or 
above) for alcohol x ondansetron x time: “desire for a drink”, “optimistic”, 
“cheerful”, and “clear-headed”', additionally, post-hoc one-way repeated 
measures ANOVA of alcohol and placebo ondansetron Vs alcohol and 
ondansetron at individual time points were carried out.
A paired t-test was used to compare mean breath alcohol measurements 
20 min. post alcohol for the alcohol and placebo ondansetron Vs alcohol and 
ondansetron groups.
The mean SRT before the drink was used as the baseline and the post 
drink mean SRT was subtracted from it to derive the average change in 
reaction time. For the four groups, a one-way repeated measures ANOVA was 
performed.
Results
Table I shows that alcohol produced significant effects (alcohol x time 
interactions) on all VAS ratings except 'confident ’. The effects of alcohol were 
significantly attenuated by ondansetron (alcohol x ondansetron x time 
interactions) for 6 of the 10 VAS scales: “cheerful” (F=2.34; df=7,105; 
p=0.029); “confident” (F=3.70; df=7,105; p=0.001); “energetic” (F=2.92;
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df=7,105; p=0.008); “optimistic” (F=2.54; df=7,105; p=0.018), “content” 
(F=2.91; df=7,105; p=0.008), and “desire for a drink” (F=6.92; df=7,105; 
p<0.0001). Ondansetron did not modify the effect of alcohol on the following 
measures: “feel good” (F=1.29; df=7,105; p=0.26); “clear-headed” (F=0.95; 
df=7,105; p=0.47) or “relaxed” (F=1.08, df=7,105; p=0.38). Ratings of 
“agreeable” showed a significant alcohol x ondansetron interaction (F=6.03; 
df=l,15; p=0.027) but the interaction between alcohol, ondansetron and time 
was not significant (F=0.90; df=7,105; p=0.51). Table II shows the inter-group 
comparisons and confidence intervals for mean change in visual analogue scales 
from baseline. From this it can be seen that compared to placebo, ondansetron 
by itself had no effect on any of the VAS ratings. No tests for carryover effects 
were significant at the 5% level (data not shown).
There was no effect of ondansetron on breath alcohol concentration, as 
measured by a Lion SD-2 alcometer (breathalyser), 20 min. after alcohol 
ingestion: (mean (s.e.m) concentration following alcohol and placebo, 30(2.0} 
mg/100 ml; following alcohol and ondansetron, 30(1.9} mg/100 ml).
The mean change (s.e.m) in SRT from baseline following the drink was 
as follows: placebo alcohol and placebo ondansetron 17.46 ± (13.48) 
milliseconds; placebo alcohol and ondansetron 9.33 ± (13.79) milliseconds; 
alcohol and placebo ondansetron 21.03 ± (11.24) milliseconds; alcohol and 
ondansetron 14.19 ± (7.2) milliseconds. There were no significant main effects
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for alcohol F=0.12; df=l,2; p=0.72 or ondansetron F=0.41; df=l,2; p=0.52, or 
alcohol X ondansetron interactions F=0.001; df=3,60; p=0.95.
Discussion
These findings suggest that 5-HTg receptor blockade attenuates some 
of the subjective effects of alcohol on mood, and reduces the subjective desire 
to drink. The effect of ondansetron to decrease some of the pleasurable effects 
of alcohol may be correlated with a reduction in its reinforcing properties of 
alcohol but it is important to point that this was not measured directly. It may 
be that a reduction in the pleasurable effects of alcohol by ondansetron could 
decrease alcohol consumption in a free-choice paradigm. Interestingly, animal 
studies indicate that a decrease in the reinforcing effects of a drug does not 
necessarily lead to reduction in drug-seeking behaviour. Indeed, partial 
blockade of the reinforcing effects of other drugs of abuse such as 
amphetamine and cocaine have been shown to elicit the opposite response, as 
the animal works harder to overcome to obtain the reinforcer (Davis and 
Smith, 1975; De Wit and Wise, 1977).
It has been suggested that increased release of dopamine in the nucleus 
accumbens may play a critical role in mediating the reinforcing effects of drugs 
of abuse. If ondansetron does attenuate the reinforcing properties of alcohol in 
humans it is tempting to speculate that this effect could be due to blockade of
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dopamine release in the nucleus accumbens (Carboni et al, 1989; Fadda et al, 
1989). There is, however, no direct evidence for this proposal at present.
Importantly, the psychological effects of alcohol may involve 
neurochemical mechanisms other than alterations in 5-HT or dopaminergic 
activity. For example, the sedative and anxiolytic effects of alcohol have been 
linked to increased activity at GAB synapses. In this respect it is of interest 
that ondansetron did not significantly reduce the effect of alcohol on subjective 
ratings of “clear-headed” and “relaxed”. However, at present, it is not 
possible to link with certainty any particular psychological effect of alcohol 
with a specific neurotransmitter system. For example, it is worth noting that 
although ondansetron appeared to attenuate several of the pleasurable effects 
of alcohol it did not significantly alter ratings of “feel good”. Currently, there 
is no obvious explanation for this discrepancy.
It is important to consider that ondansetron may have altered the gastric 
absorption of alcohol. In gainsay, there was no effect of alcohol on breath 
alcohol concentration and a previous pharmacokinetic study using a much 
larger dose of ondansetron (24 mg) found no effect on blood alcohol levels 
(Preston C, personal communication). The lack of a main effect of alcohol on 
SRT reflects, perhaps, that impairment of performance is modest at low doses 
of alcohol. It is also possible that small deficits in performance were masked by 
notable inter-subject variability. In addition, there was no evidence that the 
small deficit observed was reversed by ondansetron suggesting that non 5-HTg
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interactions may mediate this effect. Further studies are needed to confirm and 
extend the current preliminary findings, and to assess the effect of 5-HTg 
receptor antagonists on drinking behaviour.
Conclusions
1. Ondansetron attenuates some alcohol-induced mood changes and the desire 
to consume alcohol. I have hypothesized that this effect of ondansetron is 
correlated with a decrease in the reinforcing properties of the drug, though this 
was not measured directly. It is of interest that a preliminary clinical trial by 
Sellers et al. (1992) found that six weeks of treatment with ondansetron, albeit 
at a lower dosage (0.25 mg bd ), reduced the alcohol intake of heavy drinkers; 
however, this effect was only apparent after the drug was stopped. It also 
highlighted the suggestion from animal studies that the dose-response 
characteristics of ondansetron might be non-linear (Costall et al., 1987) 
Importantly, however, in a recent human laboratory study of similar design to 
this experiment, Jasinski et al. (1992) found that both 0.25 mg and 2 mg iv of 
ondansetron attenuated the subjective feeling of “how much like the cocaine 
(in this case, cocaine was the reinforcer) ? t h e  effect was much greater at the 
higher dose. It is tempting to speculate that the higher intravenous dose (2 mg) 
may be roughly equivalent to a dosage of about 4 mg orally as approximately 
50-60% of the oral preparation is bioavailable (Pritchard, 1992). If it turns out 
that lower doses are more effective in clinical trials than human laboratory 
experiments it raises the interesting possibility that the therapeutic window of
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the drug may be differentially sensitive to subjective and behavioural effects, 
and possibly, paradigm; indeed, there is some recent evidence to support this 
hypothesis (Cooper et al., 1993). Further clinical trials are needed to confirm 
the efficacy of ondansetron to diminish drinking in alcohol abusers. In addition, 
there is a need to investigate the dose-response characteristics to the 
psychological effects of ondansetron in humans. These investigations are, 
however, outside the scope of the present thesis. It is also possible that future 
clinical trials will be conducted using second generation 5-HTg antagonists 
such as GR 68775 which apparently have linear dose-response characteristics 
(Costall et al., 1992). Experiment 2 is a replication of the present study using a 
simpler design and a different group of subjects.
2. While there was no significant difference in breath alcohol readings after 
alcohol and placebo compared with alcohol and ondansetron, this measurement 
can only be reliably attained on the breathalyser 20 min. post alcohol. Thus, this 
measurement may simply reflect ‘ceiling’ levels following absorption. It was, 
therefore, not possible to exclude the possibility that there might have been 
differences in serum alcohol concentration between the two groups earlier or 
across the time course of the experiment. To exclude this possible confounding 
variable I conducted a pharmacokinetic study (see experiment 3).
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EXPERIMENT 2 
Objective
To confirm whether ondansetron attenuates some of the positive 
subjective effects of alcohol and the desire to drink as shown in experiment 1.
Method
Subjects
Twelve healthy male volunteers (mean age 29.8 years; range 20-48 
years) who were social drinkers (mean alcohol intake in units/week {s.e.m}, 
9.3 {1.2}) were studied. Recruitment and assessment of subjects to confirm 
there was no history of substance misuse or psychiatric disorder, and that they 
were in good physical health was as for experiment 1. Subjects gave written 
informed consent to participate in the study. Written consent was also obtained 
from their family doctors. Permission to conduct this study was provided by the 
Oxford District psychiatric Research Ethics Committee.
VAS
For this experiment, the most sensitive VAS measures to acute alcohol 
fi'om experiment 1 were chosen. They were: '"agreeable”, "cheerful”.
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"clear-headed”, "confident”, "content”, "optimistic”, and "desire for a 
drink”. A new variable, "buzz”, was added to assess the immediate positive 
effects of alcohol ingestion, making a total of eight variables for the VAS. 
Subjects rated their subjective feelings at specified time points by placing a 
mark on a 100 mm line anchored with the endpoints of ‘Not at all’ on the left 
hand side and ‘Extremely’on the right. VAS were scored for each time point by 
measuring the distance between the left hand side endpoint and the subject’s 
mark.
Design
The laboratory setting was as in experiment 1. The familiarization 
procedure prior to testing, and the time interval between test days was as in 
experiment 1. In contrast to experiment 1 there was no computerized cognitive 
performance test. Each subject received the following two treatments in a 
double-blind, randomized, crossover design: (a) alcohol (580 ml of 3.6% 
alcohol content by volume of lager) and ondansetron (4 mg orally); (b) alcohol 
and placebo ondansetron.
Subjects were studied after a four hour fast at 1400h when they 
received either ondansetron or matching placebo. Alcohol was given 60 min. 
later. VAS on 100 mm lines were completed 20 and 10 min. before 
ondansetron or placebo ondansetron, just before alcohol (time 0), and then 3, 
5, 10, 15, 20, and 35 min after alcohol. Subjects were not allowed to refer to
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previously completed VAS. Breath alcohol concentration was measured 20 min 
after alcohol with a Lion SD-2 alcometer (breathalyser).
Data analysis
For the two treatment groups, the median and interquartile range of the 
VAS rated 10 min. before ondansetron were compared with those scored just 
before alcohol (time 0) using the Wilcoxon Signed-Rank test. As this period 
includes the time when subjects had received only ondansetron or matching 
placebo, this comparison was used to determine if there was any independent 
effect of ondansetron. VAS scored post alcohol (i.e. after time 0) were 
subtracted from those rated just before the drink of alcohol (i.e. at time 0). 
Area under curve analysis (AUC) from baseline were calculated on the data. 
The median and interquartile ranges of the AUCs for the VAS scores were 
determined for the treatment groups and compared using Wilcoxon 
Signed-Rank test. The mean breath alcohol concentration 20 min. post alcohol 
was determined for both groups and compared using a paired t-test.
Results
There were no independent effects of ondansetron on any of the VAS 
ratings (table III). Alcohol and ondansetron produced significantly lower 
ratings than alcohol and placebo on the following VAS ratings: "agreeable ”, 
"confident”, "content”, "optimistic” and "desire for a drink”. There was no
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significant difference between the two groups on: "buzz”, "cheerful”, 
"clear-headed”, and "confident” (table IV and fig. II). Non parametric 
statistical methods were used for these analyses because the data was not 
normally distributed.
There was no significant difference in mean alcohol concentration 
{s.e.m} following alcohol and placebo compared with alcohol and ondansetron; 
27.1 ± {2.6} mg/ml and 30.00 ± {3.4} mg/ml respectively (t=1.0; df=ll; 
p=0.33).
Conclusion
The pleasurable effects of alcohol, and particularly the desire or urge to 
drink, are important to its reinforcing properties. In a recent experiment. De 
Wit and Chutuape (1993) have confirmed my finding that the desire for alcohol 
increases over time (up to 60 min.) following oral administration of 0.25 to 0.5 
g/kg of alcohol. In addition they showed that subjects were more likely to 
chose more alcohol over money if they had received an alcohol pre-load. It is, 
therefore, an importance that the major finding of these experiments is that 
ondansetron (4 mg orally) has been confirmed to reduce the "desire for a 
drink” following a small dose of alcohol. It is tempting to speculate that with a 
larger number of subjects ondansetron would have been shown to attenuate 
"cheerful” and "confident” and "buzz” as the AUC scores for the alcohol 
and ondansetron group were markedly less than those for subjects who
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received alcohol and placebo. It is, however, also conceivable that the effect of 
ondansetron on alcohol-induced mood change on these measures lack 
robustness.
Future research outside the scope of this thesis will need to explore 
whether the ability of ondansetron to attenuate the "desire to drink” will lead 
to a measurable reduction in alcohol consumption in a laboratory setting. If this 
is successful, clinical trials in heavy drinkers would be warranted.
EXPERIMENT 3 
Hypothesis and objective
In the previous experiments I found that a single oral dose of the 5-HTg 
antagonist, ondansetron (4 mg orally), attenuated the positive subjective effects 
of a small oral dose of alcohol in healthy male volunteers. While this effect is 
consistent with data from animal studies that 5-HTg receptor blockade can 
diminish the reinforcing properties of drugs of abuse (including alcohol), 
perhaps by opposition of dopaminergic function in the nucleus accumbens 
(Carboni et al., 1989; Wozniak et al., 1990; Yoshimoto et al, 1992), I could 
not exclude the possibility that ondansetron might have altered the 
bioavailabilty of alcohol. For instance, there is evidence that ondansetron 
inhibits gut motility (Talley et al., 1990). Thus, it is conceivable that 
ondansetron might have impaired the absorption of alcohol into the
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bloodstream. In this experiment I investigated whether ondansetron impairs the 
absorption of a small dose of alcohol from the gut.
Method
Subjects
Eight male volunteers (mean age 31.1; range 20-51 years) who were in 
good physical health and who had no history of mental illness (including 
substance abuse) were studied.
Laboratory
Subjects were studied while sitting upright in bed in a clinical testing 
room (approximately 6 x 8 feet in dimension) equipped with cardiovascular 
monitoring equipment.
Design
Subjects were tested twice in a double-blind, randomized, cross-over 
fashion. After a 4 hour fast at 1400 h, an intravenous cannula was inserted into 
an arm vein and it was kept patent by flushing with 5 ml of Hepsal solution 
(heparin sodium 10 units/ml). Subjects then received ondansetron (4 mg) or 
matching placebo. Sixty minutes later they consumed a drink of alcohol (580
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ml of 3.6% alcohol content by volume of lager + 20 ml of lime juice) over a 
period of 1-2 minutes. Venous blood samples for alcohol estimation were 
drawn from the indwelling cannula at 5 minute intervals following alcohol 
ingestion for 30 minutes. Serum alcohol concentration was measured by a 
standard gas chromatography method.
Breath alcohol concentration was measured using a Lion SD-2 
alcometer 20, 25, and 30 min. post alcohol.
Data analysis
For the two treatment groups - alcohol and ondansetron Vs alcohol and 
placebo ondansetron - means and standard errors, and the 95% Cl for the 
difference between the groups were calculated for serum alcohol levels 3, 5, 
10, 15, 20, 25, and 30 min. post alcohol. In addition, a two-way repeated 
measures analysis of variance (ANOVA) was used to compare the groups.
For both treatment groups, means and standard errors of breath alcohol 
concentration 20, 25, and 30 min. post alcohol were calculated. The correlation 
between breath and serum alcohol concentration 20, 25, and 30 min. post 
alcohol for each treatment group was determined using Pearson’s correlation 
coefficient.
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Results
Table V shows the means and standard error, and 95% Cl for the 
difference between the two treatment groups on serum alcohol concentration. 
Serum alcohol concentration rose swiftly over time following the drink of lager 
(F=30.4, df=6,42; p<0.001). There was, however, no main effect of 
ondansetron (F=0.44, df=l,42; p=0.53) and no interaction between the effects 
of ondansetron and time (F=0.29, df=6,42p=0.93) (see fig. III}.
Table VI shows the comparison in means and standard errors, and 
correlation coefficients 20, 25, and 30 min. post alcohol for breath and serum 
alcohol concentrations between the treatment groups. The overall correlation 
coefficient between serum and breath alcohol concentration for the: (a) alcohol 
and ondansetron group was 0.83; p<0.0001; (b) alcohol and placebo 
ondansetron group was 0.84; p<0.0001.
Conclusions
While there was good agreement between breath and serum alcohol 
concentration for both groups taking into account all the readings post alcohol, 
there was little concordance at individual time points. In addition, breath 
alcohol readings were always higher than serum alcohol measurements. This 
may be due to marked inter-subject variability on breath alcohol readings, or 
contamination of measurements from gaseous alcohol in the nasopharynx, or
81
both. Importantly, however, the serum alcohol measurements confirm that 
ondansetron does not alter the absorption of a small dose of alcohol into the 
blood stream. These results are consistent with a previous study that used 
larger doses of alcohol and ondansetron (24 mg) where again no effect of 
ondansetron on the pharmacokinetics of alcohol was apparent (Preston, C;
ondansetron topersonal communication). I, therefore, conclude that the ability of 
diminish some of the positive subjective effects of alcohol is unlikely to be due 
to changes in alcohol absorption from the gut.
EXPERIMENT 4 
Hypotheses and objectives
There is considerable evidence that the reinforcing effects of 
amphetamine are mediated by dopaminergic pathways. For instance, rats can be 
trained to lever press for amphetamine (Pickens and Harris, 1968; Wise et al., 
1976), an effect which is attenuated by the administration of the D2 receptor 
antagonist, pimozide (Yokel and Wise, 1985). Although amphetamines also 
facilitate the release of adrenaline from nerve terminals, amphetamine-induced 
responding is not attenuated by adrenergic antagonists such as 
phenoxybenzamine and propanolol (for a review see Neilsen and Anderson,
1992). while amphetamine reliably produces CPP in animals (Leone and Di 
Chiara, 1987; White et al., 1987), CPP to amphetamine is blocked by D2 
receptor antagonists such as haloperidol (Mithani et al., 1986) and 6-OHDA
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lesions of the nucleus accumbens (Roberts and Koob, 1982). Similarly, in 
humans, the psychostimulant properties of amphetamine are attenuated by 
pimozide (Silverstone et al., 1980). It is, therefore, of interest that, in animals, 
5-HT3 receptor antagonists have been shown to inhibit amphetamine-induced 
hyperactivity (Costall et al., 1987) and CPP (Van der Hoek, 1989) and other 
dopamine-mediated behaviours in some paradigms (Imperato and Angelucci, 
1989; Van der Hoek, 1990b; Chen et al., 1991) although there have been 
contradictory findings (Carboni et al., 1989; Moser, 1992). As the reinforcing 
properties of amphetamine are correlated with its positive subjective effects 
(Stolerman, 1992) it is hypothesized that S-HTg receptor antagonists would 
attenuate these mood changes in humans, thereby reducing its reinforcing 
value.
It is well established that pharmacological doses of amphetamine (2.5 
mg to 30 mg orally) increase the speed of response, vigilance and attention on 
computerized tests (Spiegel 1979 and 1989; Harvey, 1987). These responses 
appear to be mediated by the enhanced release of dopamine and noradrenaline. 
Interestingly, 5-HT] receptor antagonists, which oppose mesolimbic dopamine 
activity and inhibit 5-HT neurotransmission, have been shown to improve 
learning and performance on memory dependent tasks in animals. Additionally, 
in humans, 5-HTg antagonists improve age-associated impairments, possibly by 
facilitation of cholinergic neurotransmission (Barnes 1989a and b; Crook and 
Larkin, 1991). To date, there has, however, been no study of the effects of 
5-HT] antagonist/amphetamine interaction on cognitive performance.
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In animals, ^/-amphetamine causes the release of both noradrenaline and 
dopamine (Carlsson, 1970). In addition, brain stimulation, lesioning, and 
behavioural studies in animals suggest that it is this increased catecholamine 
availability that is responsible for amphetamine’s ability to suppress food 
intake. Anorexia induced by amphetamine (at a dose of 1.25 mg/Kg) and 
mazindol (7.5 mg/Kg) is blocked by lesions of the ventral noradrenergic bundle 
(Samanin et al, 1977), and disruption of catecholamine synthesis by 
alpha-methyl-para-tyrosine reduces food intake (Baez, 1974). Notably, 
amphetamine-induced anorexia is only partially attenuated by dopamine 
receptor blockade with a-flupenthixol at relatively high (Garattini and Samanin, 
1976) but not at low dosages (Burridge and Blundell, 1979). Hence, it has been 
suggested that noradrenergic rather than dopamine stimulation may be more 
critical to maintaining anorexia following amphetamine in animals (Samanin et 
al., 1978; Samanin and Garattini, 1982). In humans, (/-amphetamine also 
induces anorexia, an effect which is attenuated by the D2 receptor antagonist,
I a-flupenthixol (Garattini and Samanin, 1976; and for a monograph see 
Silverstone, 1992). However, amphetamine-induced anorexia is not attenuated 
in humans by the noradrenergic blocking agent, thymoxamine (Goodall et al., 
1987). Since 5-HTg receptor antagonists oppose mesolimbic dopamine 
function, it would be predicted that 5-HTg antagonists, which oppose 
mesolimbic dopamine activity, might attenuate the anorectic effects of 
amphetamine.
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The present pilot investigation was the first human study of the effects 
of 5-HT3 antagonists on amphetamine-induced behaviours. As there had been 
some contradictory findings from animal experiments, the objectives were to 
investigate whether there was any evidence that ondansetron could attenuate 
the ability of amphetamine to induce positive subjective mood and anorexia, 
and to study 5-HT3 antagonist/amphetamine interactions on reaction time and 
vigilance. I planned to confirm my positive findings in a follow up study.
M ETHOD
Subjects
Nine subjects between the ages of 21 and 47 years (mean age 34.1 
years) were screened by psychiatric interview and medical examination to 
confirm they had no history of mental illness (including substance misuse), and 
were in good physical health before they were entered into the study. Subjects 
gave informed written consent to participate in the study. Written permission 
was also obtained from their family doctors. Permission to conduct the study 
was granted by the Oxford District Psychiatric Research Ethics Committee.
Laboratory
Laboratory conditions were as described in previous experiments 1 and 2.
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Rating Scales
Subjects rated their subjective feelings at specified time points 
on six visual analogue scales (VAS) items by placing a mark on a 100 mm line 
anchored with the endpoints of ‘Not at all’ on the left hand side and 
‘Extremely’on the right. VAS were scored for each time point by measuring 
the distance between the left hand side endpoint and the subject’s mark. The 
adjectival variables for the VAS were derived from ratings which had been 
shown to be sensitive to the effects of amphetamine by other experimenters 
(Silverstone et al., 1968 and 1980; Jacobs et al., 1986). They were: "hunger”, 
"X>oû\Â\G mood”, "energy”, "alertness”, "restlessness”, mdi "irritability”.
The subjects’ report of overall subjective abnormality was rated on a 
three point scale. The points on the scale were: 0-normal, 1-slightly abnormal, 
light-headed, or “high”, and 2-definitely abnormal, light-headed, or “high”.
Computerized Tests
1. The simple reaction time (SRT) test used was as in experiment 1.
2. The modified Stroop colour naming task measures interference to the 
cognitive processing of mood congruent words. It is also a test of vigilance as 
individuals are required to name the colour of a word as soon as it is detected. 
Five different colours are presented in random order. Distraction is produced 
by asking a person to name the colour of a word with emotional significance
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with respect to their mood state. For instance, an anxious person would be 
expected to spend more time processing threat related words such as “panic” 
(Stroop, 1935). In this experiment, the Stroop was modified such that the 
words generated by the programme fell into one of three groups: low-mood 
(e.g. downcast), elevated mood (e.g. happy), and neutral words (e.g. 
typewriter). There were 48 words in each group, making a total of 144, and the 
presentation of words was in a random fashion. The words were presented on 
screen for 15 milliseconds; half the words were covered by a string of 
characters of a certain colour (i.e. “masked”). Subjects were required to name 
the colour of the words if they were “unmasked”, and of the masking string if 
they were covered. The time taken to name each colour was recorded (in 
milliseconds) using a voice activated microphone connected a computer fitted 
with a Labtender timer card. The Stroop has been reliably used as a measure of 
focused attention to nicotine-induced improvements (Wesnes and Warburton, 
1978), difficulty in concentrating produced by atropine (Callaway and Band, 
1958), and deficits caused by scopolamine (Wesness and Revell, 1984). It was 
expected that amphetamine would enhance Stroop performance, and possibly, 
increase selective attention to mood-elevating words. “Masking” of some 
words was adopted because there is some evidence that this increases the 
sensitivity of the test.
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Systolic blood pressure
Measurements of systolic blood pressure (using a mercury 
sphygmomanometer) were taken by a blinded observer.
Design
Subjects received the following treatments in a double-blind, 
randomized, cross-over design: (1) placebo ondansetron and placebo 
amphetamine; (2) placebo ondansetron and amphetamine (15 mg); and (3) 
ondansetron (12 mg in total) and amphetamine. In the twenty four hour period 
prior to the testing, subjects received pre-loading with ondansetron or matching 
placebo (to obtain good serum levels of ondansetron) in two doses of 4 mg 
each every 12 hours, making a total of 8 mg. Subjects fasted overnight and 
received the third of three 4 mg doses of ondansetron or matching placebo at 
09.00 h (baseline). Thus, although there was no ondansetron and placebo 
amphetamine group, independent effects of ondansetron were estimated by 
comparing baseline scores. At 09.30 h, thirty minutes post baseline, subjects 
received 15 mg of amphetamine or matching placebo. VAS were completed 
from baseline, and every 30 min. from 10.30 h to 12.30 h (i.e. from 1 to 3 
hours following amphetamine or matching placebo). Subjects were not allowed 
to refer to previously completed VAS. In addition, at 12.30 h subjects assessed 
their overall subjective abnormality during the session. The timing of the blood 
pressure measurements were as for the VAS. The blood pressure measurement
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at 0900 h was taken as the baseline reading and subsequent recordings were 
subtracted from this. The computerized tests were administered at baseline 
(0.900 h), and 2 hours and 4 hours following amphetamine or matching 
placebo. The Stroop was administered prior to the SRT. Test days were 
separated by a washout period of at least seven days.
Data analysis
Differences between test days in mean scores on the VAS were 
assessed using the Student’s two-tailed paired t-test. Changes in the mean 
ratings for overall subjective abnormality were analyzed by the Wilcoxon’s 
signed rank test for paired samples. Paired t-tests were used to compare mean 
differences in systolic blood pressure in the 1 h to 3 h period post 
amphetamine. On the computerized tests, paired t-tests were conducted on the 
mean change in time from baseline to 2 h and 4 h post-amphetamine. In the 
Stroop colour naming task, independent effects on the three lists (low mood, 
elevated mood, and neutral words) were sought using a three-way repeated 
measures analysis of variance (ANOVA). Descriptive statistics are given as 
mean ± s.e.m, except for the overall subjective abnormality scale which is 
defined by the median and range.
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RESULTS
Visual analogue Scales
Amphetamine produced a decrease in self-ratings of hunger compared 
with placebo. There were significant differences between: (a) placebo and 
placebo, and (b) placebo ondansetron and amphetamine which peaked 2.5 h 
following amphetamine (t = 2.46; df = 8; p<0.05). Following ondansetron 
pre-treatment, however, the decrease in hunger produced by amphetamine was 
attenuated - there was a significant difference between: (i) placebo ondansetron 
and amphetamine, and (ii) ondansetron and amphetamine at 2.5 h (t = 2.37; 
df = 8; p<0.05). Baseline ratings of hunger were not altered by ondansetron 
pre-treatment (data not shown) {see fig. IV}. Amphetamine caused a small but 
statistically insignificant increase, which peaked at 2 h, in VAS for: (a) 
"restlessness” (mean change in placebo and placebo group 9.6 ± 2.4 mm Vs 
mean change in the placebo ondansetron and amphetamine group 20.7 ± 5.6 
mm), and (b) "irritability” (mean change in placebo and placebo group 7.3 ± 
2.4 mm Vs mean change in the placebo ondansetron and amphetamine group 
10.6 ± 5.6 mm Vs mean change in ondansetron and amphetamine group 4.0 ± 
4.9 mm). There were no statistically significant changes in the VAS for 
“positive mood”, "energy”, or "alertness” in the placebo ondansetron and 
amphetamine group compared with the placebo and placebo group. 
Nevertheless, there were small increases ratings of “positive mood” in the
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placebo and amphetamine group (9.2 ± 6.0 mm) compared with the placebo + 
placebo group (5.3 ± 2.9 mm).
Overall subjective state
Amphetamine significantly increased ratings of overall subjective 
abnormality, and this increase was attenuated by ondansetron. The median 
score for the placebo ondansetron + amphetamine group was 2 (range 1-2); in 
contrast, median scores for the placebo + placebo group was 0.5, range 0-1 (Z 
= 2.59; p<0.05), and for the ondansetron + placebo amphetamine group the 
median was 1, range 0-2 (Z = 2.12; p<0.05) {see fig. V}.
Computerized tests
In the Stroop colour naming task, a three-way repeated measures 
ANOVA (i.e. main effect of word type x treatment group x time) was used to 
discover whether there was an independent effect of word type (fi-om the three 
word lists). As there was no independent effect of word type (F=2.32; 
df=2,144; p = 0.10), all three different word types were analyzed together. 
There was a significant main effect of amphetamine (F=6.67; df=2,144; 
p<0.02). There was no significant difference in the placebo and placebo group 
from baseline in the mean time taken to name the colour from baseline at either 
2 h (mean change -1.7 ± 11.2 ms) or 4 h (mean change + 21.4 ± 16.3 ms). In 
the placebo and amphetamine group the mean change from baseline was
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significant at both the 2 h (mean change - 41.4 ± 11.6 ms; t = 2.51; df = 8; 
p<0.02) and at 4 h (mean change - 24.9 ± 16.0 ms; t = 2.16; df = 8; p<0.05). 
Pre-treatment with ondansetron did not attenuate the effects of amphetamine 
on the Stroop. Thus, the mean change from baseline in the ondansetron and 
amphetamine at 2h was (mean change - 37.4 ± 10.2 ms; t = 2.84; df = 8; 
p<0.01) and at 4h (mean change - 23.1 ± 11.0 ms; t = 2.07; df = 8; p<0.05) 
{see fig. VI}.
In the SRT, amphetamine caused a marked decrease from baseline at 2 
h which reached statistical significance at 4 h. Thus at 4 h the mean change 
from baseline in the placebo + placebo group was 3.6 ± 6.1 ms; for the 
amphetamine + placebo ondansetron group it was - 16.3 ± 7.0 ms; t = 2.33; df 
= 8; p<0.05). Ondansetron did not attenuate the effect of amphetamine, and in 
the ondansetron + amphetamine group the mean change fi*om baseline at 4 h 
was - 14.1 ± 6.8 ms; t = 2.06; df = 8; p<0.05) {see fig. VII).
Systolic blood pressure
Mean systolic blood pressure changed little for the placebo and placebo 
group during the study (mean increase + 0.27 ±3.2  mm Hg). In the placebo 
and amphetamine group mean systolic pressure rose significantly compared 
with the placebo + placebo group (mean change + 6.6 ±1.9 mm Hg; t = 3.3; df 
= 44; p<0.002). Ondansetron had no effect on this amphetamine-induced rise in 
systolic blood pressure with the mean increase in the ondansetron and
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amphetamine group being + 6.4 ±3.3 mm Hg, significantly greater than the 
placebo + placebo group (t = 3.7; df = 44; p<0.001) {see fig. VIII).
DISCUSSION
There are four methodological limitations to this preliminary study. 
Firstly, the dose of amphetamine used, 15 mg, appears to have been too low 
as it did not produce significant changes in VAS ratings of “positive mood”, 
"alertness”, "irritability”, and "energy”, as is consistently seen with higher 
doses of between 20 mg and approximately 35 mg in normal human volunteers 
(Jacobs et al., 1986; Angrist et al., 1987). It is, therefore, not possible to 
determine whether or not these individual psychological changes would have 
been attenuated by ondansetron. Secondly, there was no ondansetron and 
placebo amphetamine group. Thus, independent effects of ondansetron could 
not be confidently excluded, and it was not possible to segregate its impact, if 
any, on the amphetamine and ondansetron group. Thirdly, serum levels of 
ondansetron and amphetamine were not measured. It is, therefore, not possible 
to exclude pharmocokinetic explanations for the effect of ondansetron on 
amphetamine-induced psychological changes. This is particularly pertinent as 
ondansetron has been shown to inhibit gut motility (Talley et al., 1990). It is, 
however, equally important to point out that in experiment 3 I was unable to 
uncover any evidence that 4 mg of ondansetron impaired the absorption a small 
dose of alcohol. This opinion is shared by an independent experimenter who 
found no significant effects of up to 24 mg of ondansetron on alcohol
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absorption (Preston, C; personal communication). Fourthly, the predictive 
power of the study is hampered by the small number of subjects and modest 
but biologically relevant findings may go undetected.
The mechanism by which ondansetron attenuates amphetamine-induced 
anorexia is of particular relevance. Microinjection studies in rodents have 
suggested that the anorexic effect of amphetamine is mediated largely through 
facilitation of noradrenergic and dopaminergic neurotransmission (Blundell, 
1985) in the lateral hypothalamus (Hoebel et al., 1989) and perhaps the nucleus 
accumbens (Cooper, 1991). Thus, the partial attenuation of 
amphetamine-induced anorexia by ondansetron is consistent with the effects on 
hunger of drugs which antagonize amphetamine-mediated dopamine release in 
animals (Samanin et al., 1977; Samanin and Garattini, 1982).
Amphetamine caused a significant elevation in ratings of overall 
subjective state, and a trend towards elevation of “positive mood”. The 
biochemical mechanism underlying this change is uncertain. Nevertheless, in 
humans, amphetamine-induced mood elevation or arousal can be attenuated by 
dopaminergic but not noradrenergic antagonists (Gunne et al., 1972; 
Silverstone et al., 1980). This implies that amphetamine-induced mood 
elevation may be attributable to increases dopamine release. Animal studies of 
reward behaviour, probably the best model of mood elevation, have repeatedly 
shown that increased dopaminergic neurotransmission in the nucleus 
accumbens is crucial to the development, direction, and maintenance of reward
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behaviour (Yokel and Wise 1976; Lyness et al., 1979; Stolerman, 1992). It is, 
however, important to point out that the present study did not produce 
significant increases in energy, alertness, or restlessness, all of which when 
induced by larger doses of amphetamine can be attenuated by dopamine 
receptor blockers (Silverstone et al., 1980; Jacobs and Silverstone, 1986). It is 
possible that the measurement of overall subjective state was either sensitive 
enough to pick up small amphetamine-induced changes in mood, or related to 
some other biochemical process. Repeating this experiment using a higher dose 
of amphetamine is critical to resolving this issue. Given that overall subjective 
state may be a global measure of amphetamine-induced mood, it is of 
importance that this was attenuated by ondansetron. This finding is in keeping 
with the results of a recent human experiment whereby ondansetron attenuated 
the "rush” of intravenous cocaine (Jasinski et al., 1992). Hence, as cocaine, 
like amphetamine, increases dopamine release in the limbic system, it is 
conceivable that the results from both these experiments represent evidence of 
attenuation of central dopamine release by ondansetron. This effect is also 
consistent with the finding in animals that 5-HT] antagonists inhibit 
amphetamine-induced hyperlocomotion (Costall et al., 1987). Notably some 
investigators have been unable to attenuate increased dopamine release 
following amphetamine with 5-HTg receptor antagonists (Carboni et al., 1989; 
Montgomery et al., 1993). However, the dosages of amphetamine used in these 
experiments were up to fifty times higher than in the study of Costall and 
co-workers (1987), the dosage of ondansetron was greater (and may have been 
subject to inactivity at the higher dose due to the non-linear dose-response
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characteristics of ondansetron), and the route of drug administration was 
peripheral rather than systemic. It may be that 5-HT] antagonists can act either 
pre-synaptically to inhibit dopamine release or post-synaptically to attenuate 
the effects of increased dopamine release, or that S-HTg antagonists may only 
inhibit reliably the action of drugs which increase dopamine neurotransmission 
transynaptically. Thus, it can be argued that the effects of drugs such as 
alcohol, morphine, and nicotine which indirectly facilitate dopaminergic 
neurotransmission transynaptically and which depend upon transmission at 
excitatory 5-HT] receptors, presumably located pre-synaptically, are those 
most likely to be inhibited by 5-HT] antagonists. In contrast, amphetamine and 
cocaine act by directly releasing dopamine from synaptic terminals or 
preventing its re-uptake. Dopamine cell firing is not increased and, therefore, 
amphetamine or cocaine mediated behaviours may not be affected by the 
activity of 5-HT] antagonists at presynaptic 5-HTg receptors. In sum, the 
precise biochemical mechanisms which underlie the effects of 5-HT] receptor 
antagonists on amphetamine-induced behaviour require clarification from 
fijrther studies.
The findings of the present experiment are in keeping with the view that 
amphetamine improves performance in psychomotor tasks of speed and 
vigilance (Spiegel, 1989). It has been hypothesized that dopaminergic 
mechanisms may be involved in the control of these processes. Ondansetron 
had no obvious effect on cognitive performance and this is in keeping with a 
previous study in human volunteers (Hall and Ceuppens, 1991). Notably,
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however, this study did not contain an ondansetron alone group which will be 
needed to confidently ascertain the effect of 5-HT3 receptor antagonism on 
cognitive performance in humans. Further studies will, therefore, have to 
include more sensitive tests of focused attention such as the rapid information 
processing task, and subjects should, perhaps, be trained to ‘ceiling’ levels 
before testing.
Amphetamine administration increases the release in the brain of 
noradrenaline, dopamine, and serotonin (Carlsson, 1980; Blundell, 1985; 
Hoebel et al., 1989). The finding fi’om the present experiment of a rise in 
systolic blood pressure following amphetamine is in keeping with results from 
previous studies, one of which has shown that this rise in blood pressure can be 
blocked by noradrenergic receptor antagonism (Jacobs and Silverstone, 1986). 
It is, therefore, probable that increased systolic pressure following 
amphetamine is chiefly due to noradrenaline release. In the present experiment, 
amphetamine-induced increase in blood pressure was not attenuated by 
ondansetron. In general, animal studies have not supported a role for 5-HTg 
receptor antagonists on noradrenaline release. While one in vitro study has 
suggested that 5-HTg antagonists can inhibit noradrenaline release (Feuerstein 
and Hertting, 1986) no other study to date has replicated this finding. Support 
for a lack of effect of ondansetron on noradrenaline release also comes fi^ om 
animal models of morphine withdrawal. The behavioural syndrome of morphine 
withdrawal appears to be mediated by large increases in noradrenaline release 
within the brain (Rasmussen et al, 1990; Silverstone et al, 1992) and morphine
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withdrawal can be attenuated by blockade of noradrenaline release with 
clonidine (Silverstone, 1992). In this respect it is noteworthy that ondansetron 
does not attenuate the morphine withdrawal syndrome (Higgins et al., 1991). 
Thus, the findings in the present experiment of a lack of effect of ondansetron 
on the increase in systolic blood pressure following amphetamine are in keeping 
with previous animal evidence of a lack of effect of 5-HT] antagonists on 
noradrenaline release.
CONCLUSIONS
1. Amphetamine-induced change in overall subjective state and anorexia are 
attenuated by ondansetron. The present experiment, therefore, supports the 
hypothesis that 5-HT] antagonists oppose the release of dopamine in the 
nucleus accumbens following amphetamine. Nevertheless, the psychological 
effects of amphetamine require further confirmation. In addition the anorectic 
affects of amphetamine with and without ondansetron need quantification using 
a test meal paradigm, wherein caloric intake and macronutrient selection can be 
measured directly.
2. Higher doses of amphetamine, greater than 15 mg orally, are needed to 
produce reliable elevation of mood.
3. Second generation 5-HTg antagonist such as GR 68775 with linear 
dose-response characteristics should be employed in subsequent studies.
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4. The effects of S-HTg antagonists on amphetamine-induced enhancement of 
reaction time and attention remain unclear. Further experiments should 
substitute the Stroop with, perhaps, a more sensitive measure of focused 
attention such as the rapid information processing task. Subjects should also be 
trained to achieve ‘ceiling’ levels of performance before formal testing.
EXPERIMENT 5
Hypotheses and objectives
The present study takes into consideration the lessons learnt from 
experiment 4 and explores the impact of pre-treatment with a novel second 
generation 5-HT] receptor antagonist, GR 68775, on the psychological effects 
of a higher dose of amphetamine (20 mg).
Specifically, the present study will assess the effects of GR 68775 on 
amphetamine-induced: (1) mood change - as measured by VAS and a global 
rating of subjective well being; (2) anorexia, and using a test meal, caloric 
intake and macronutrient selection; (3) enhancements in reaction time and 
vigilance
99
METHOD
GR 68755
GR 68755 is a second generation 5-HTg receptor antagonist. Animal models 
have shown GR 68755 to be active in situations which stimulate mesolimbic 
dopamine overactivity. GR 68755 inhibits locomotor hyperactivity in the rat 
caused by: (a) injection of DiMe-C7 (a neurokinin) into the ventral tegmental 
area (0.1 - lOOOj pg/kg sc); (b) continuous infusion of dopamine into the 
nucleus accumbens (1 ng - 100^  pg/kg ip), and (c) injection of amphetamine 
into the nucleus accumbens (100 ng intra accumbens). It has also been shown 
to improve cognitive performance in the marmoset at a dose of 0.1 ng to 1 
mg/kg. Its putative advantages over ondansetron are that its dose-response 
characteristics are linear. To date, GR 68755 has been administered to 223 
healthy volunteers and has been safe and well tolerated at all dose levels studied 
(up to 16 mg bd orally for 3.5 days and 2 mg orally for 27.5 days). Adverse 
events have been minor with headaches and constipation being the most 
commonly reported. These side-effects are typical of the class of 5-HTg 
antagonists. GR 68755 is rapidly absorbed into the blood stream after oral 
administration (peak absorption 45 min to 1 h) with a relatively short 
elimination half-life in comparison to ondansetron (GR 68755 1.6 - 2.7 h Vs 
ondansetron 3 - 4 h). Its bioavailability following an oral dose is similar to that 
of ondansetron 50-60%. Thus, GR 68755 appears to be most suitable for single 
rather than repeated dosing procedures. In this respect it is of interest that, in
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humans, a single intravenous dose (2 mg) of GR 68755 reversed the 
sscopolamine-induced cognitive effects 1 h and 3 h post dosing. In addition, a 
single oral dose (1 mg) of GR 68755 has been shown to antagonize the 5-HT 
mediated intradermal flare response with a duration of action of almost 10 h 
(Glaxo, unpublished data on file). On this evidence, I decided to use a single 
oral dose (2 mg) of GR 68755 to challenge the effects of ^ /-amphetamine. To 
ensure that the antagonist, GR 68755, penetrated the central nervous system 
before the agonist challenge, GR 68755 (2 mg orally) was administered 30 min. 
before (/-amphetamine.
Subjects
Twenty six male subjects between the ages of 18 and 45 years (mean 
age 28.9 years) were recruited. Before entering the study, they had a 
psychiatric interview, medical examination, and laboratory investigations 
(haematology, biochemistry, and urinalysis for drugs) to confirm that they had 
no history of mental illness (including substance misuse) and were in good 
physical health. Urine was taken for a drug screen after each test day. 
Consequently, two subjects found to be using cannabis during the study were 
replaced. One subject failed to attend for the fourth of four test days. Written 
informed consent was provided by the subjects and their family doctors before 
they were entered into the study. Permission to conduct the study was granted 
by the Oxford District Psychiatric Research Ethics Committee (see appendix lb 
for details of volunteer screening, inclusion, exclusion and withdrawal criteria, 
and study day restrictions).
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Laboratory
Laboratory conditions were as in experiment 1, 2, and 4. Subjects made 
no contact with the experimenters except for at the start of the experiment, 
re-setting the computer for the psychometric tests, and when the test meal was 
presented. To ensure their safety, and to confirm that the ratings were 
completed as scheduled, subjects were monitored on close-circuit television.
VAS(A)
The design of the VAS was as for the previous experiments. VAS(A) 
contained 16 adjectival variables which could be subdivided into four 
categories: mood/arousal (6), reinforcement (2), hunger (2), satiety (4), and 
suspiciousness (2). The mood/arousal scales were: “confident”, “cheerful”, 
“mind-racing”, “alertness”, “restless”, and “lethargic”-, for reinforcement 
they were - “feeling good” and “getting a huzz”\ for hunger they were - 
“hungry” and “strongwish to eat”; for satiety before the test meal they were 
“7 expect to find  the meal satisfying” and “right now I  could eat a large 
amount o f food”, and after the test meal - “Ifound the meal satisfying” and 
‘7 feel fu ll”; for suspiciousness they were: “feeling bothered” and “being 
treatedfairly”.
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Global rating scale
The global rating scale measures overall subjective state on a five point 
scale: 0 - normal; 1 - slightly light-headed, restless, or speeded up; 2 - 
moderately light-headed, restless or speeded up; 3 - very light-headed, restless, 
or speeded up, 4 - extremely light-headed, restless, or speeded up. Space was 
provided at the bottom of the form for subjects to enter comments 
{appendix Ic}.
Choice o f  fo o d  items fo r  the test m eal and the test m eal paradigm, 
satiety VAS(B), and the fo o d  preference questionnaires.
In the one week prior to testing, subjects were presented with a list of 
food items fi*om which to chose the composition of their buffet style test meal 
(appendix Id}. All food items were weighed to the nearest 0.1 g before and 
after the meal. Macronutrient selection and caloric intake were calculated using 
specifically designed computer software (see Hill and Blundell, 1986 and 
acknowledgements).
VAS(B) contained items on the subjects’ satiety before and after the 
test meal. The items scored before the meal were: “/  expect to find  the meal 
satisfying” and “right now I  could eat a large amount o f food”. After the 
meal, the scales were - “Ifound the meal satisfying” and “Ifee l fu ll”.
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Two questionnaires items were also completed before and after 
the meal. The first, the forced choice questionnaire, compelled subjects to 
chose an item from a selection of each of the following macronutrients 
- protein, fat, carbohydrate, or low energy items they would like to receive 
(appendix le); specifically, the forced choice questionnaire examined 
preference for carbohydrate over protein items. The second, the free choice 
questionnaire, allowed subjects to chose whether or not they would like an 
item from any of these categories of macronutrients (appendix If}. Vegetarians 
or subjects restraining their diet would have been unable to fulfil the test meal 
criteria and were therefore not admitted into the study.
Computerized tests
1. The rationale for the SRT was described in experiment 1.
2. The Rapid Visual Information Processing Task (RVIPT) is a test of vigilance 
and attention. In this task subjects monitor digits which are presented 
sequentially on a computer screen at a rate of 100 per minute for 7.5 minutes. 
Subjects are instructed to detect and respond to targets of three consecutive 
odd or even digits as quickly as possible. Independent measures are made of 
both the speed and accuracy of decision making. The measures fi’om the task 
were: Hits - correct responses within 600 ms; delayed hits - responses 
occurring 600 - 1200 ms after the target; false alarms - incorrect responses, and
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reaction time for both hits and delayed responses. Measures were recorded for 
each 250-trial block.
Design
Subjects received each of the following four treatments in a double­
blind, randomized, Latin square design: (a) (/-amphetamine (20 mg oral) and
r  f l a c e b o
placebo GR 68755; (b) placebo GR 68755 and/(/-amphetamine; (c) placebo 
amphetamine and GR 68755 (2 mg) and (d) GR 68755 and (/-amphetamine. 
There was a 4-7 day interval between treatments. Prior to testing, all subjects 
were familiarized with the test room conditions, and trained in the use of visual 
analogue scales as described previously.
Subjects arrived in the unit 0800 hours having fasted from 23.30 h the 
previous night. A specimen of urine was taken and subjects were allowed to 
settle in the test room for 30 min. At 08.30 h and 08.40 h baseline VAS(A) (i.e. 
for mood/arousal, reinforcement, hunger, and suspiciousness) were completed. 
Baseline RVIPT and SRT were carried out immediately afterwards. At 09.00 h 
GR 68755 or matching placebo was given, and thirty minutes later (09.30 h) 
(/-amphetamine or its placebo. Subjects repeated their rating of the VAS(A) 
scales at baseline every 20 min. for the next 3 h (12.30 hours). Each set of 
VAS(A) were completed independently and subjects were not allowed to refer 
to previous ratings. After the 11.50 h VAS scales the computerized tests 
(RVIPT and SRT) were repeated. The computerized tests were chosen to
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coincide with 2 h post (/-amphetamine - the time at which peak amphetamine 
level has been previously recorded (Angrist et al., 1987). At 12.35 h subjects 
completed the pre-meal VAS(B) for satiety and the forced and free choice food  
preference questionnaires). The test meal was then brought in and subjects 
were instructed to ignore normal dietary restrictions and to eat as much as they 
wished. The time taken to eat the test meal was measured. Ten minutes after 
the meal, subjects filled in the post-meal VAS(B) and both post-meal food 
questionnaires. After this, subjects filled in the global rating questionnaire.
Data analysis
For the VAS measuring mood/arousal, reinforcement, hunger, and
suspiciousness the baseline score was taken as the mean of the 08.30 h and
08.40 h ratings. Data recorded for these VAS after the dose of amphetamine or
matching placebo were summarized by the weighted mean response over three
hours. The weighted mean was calculated by dividing the area under the curve
(AUC), obtained using the trapezoid method, by the length of time over which
the measurement was recorded (3h). In addition, the weighted mean responses for the 
visual analogue scales were analyzed using analysis of covariance allowing for effects of 
due to subjects, periods and treatments with the baseline measurement as a covariate. 
Test for carryover were also performed. Estimates of treatment effect and 95% 
confidence intervals were calculated for the differences between (/-amphetamine alone 
and placebo, GR 68755 and placebo, GR 68755 with
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(/-amphetamine and (/-amphetamine alone, and GR 68755 with (/-amphetamine 
and GR 68755 alone.
The global rating scale was analyzed by comparing treatments pairwise 
using the Wilcoxon’s signed-rank test.
Pre and post-satiety VAS(B) were recorded before and after the test 
meal respectively. Responses for the food preference questionnaires were 
displayed as mean scores ± s.e.m. Differences pre and post the test meal were 
compared using a two-way repeated measures analysis of variance (ANOVA) 
design followed by paired t-tests. All food items were weighed before and after 
the test meal. Caloric intake and macronutrient selection was calculated using 
specifically designed computer software (see Hill and Blundell, 1986, and 
acknowledgements). Means and standard errors were also determined for this 
data. Caloric intake was analyzed using a repeated measures ANOVA design 
allowing for effects of subjects, periods and treatments. Estimates of treatment 
effects and 95% confidence intervals were calculated for the differences 
between (/-amphetamine alone and placebo, GR 68755 and placebo, GR 68755 
with (/-amphetamine and (/-amphetamine alone, and GR 68755 with 
(/-amphetamine and GR 68755 alone. ANCVAs were also performed to detect 
differences between the treatment groups on macronutrient selection and 
preference for sweet or savoury foods.
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For the computerized tests, only one measurement was taken 
pre-amphetamine or its placebo, and this was used as the baseline 
measurement. The tests were summarized as the mean number of correct hits 
per minute and mean reaction time on the RVIPT, and by the mean SRT. 
Weighted geometric means were calculated for the number of correct hits on 
the RVIPT, and the reaction times were log transformed. Estimates of 
treatment effect and 95% confidence intervals between amphetamine and 
placebo, GR 68755 and placebo, GR 68755 with amphetamine and 
amphetamine, GR 68755 with amphetamine and GR 68755 were performed.
RESULTS
Subjects
Twenty six subjects were recruited. Subject 8 had a positive urine test 
for cannabis on the second of four test days and, therefore, all data was 
excluded. Subject 19 had a positive test for cannabis on the post-study check 
and data for the fourth period was excluded. Subject 12 had data from only 
three periods. Subject 14 received GR 68755/placebo in two periods. There 
were, therefore, twenty four subjects in the placebo/placebo, 
amphetamine/placebo and GR 68755 and amphetamine groups, and twenty five 
subjects received GR 68755/placebo treatment.
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FASfA)
No tests for carryover effects were significant at the 5% level. There 
were no statistically significant differences between amphetamine alone and 
placebo, or GR 68755 with amphetamine and amphetamine alone for any of the 
VAS recorded. There were statistically significant effects of treatment, and for 
differences between: (i) amphetamine alone and placebo and (ii) GR 69755 
with amphetamine and GR 68755 alone on the following visual analogue 
scales: “confidence”, “cheerfulness”, “lethargy”, “alertness”, “mind 
racing”, “hunger”, “strong wish to eat”, “feeling good” and “getting a 
buzz”. For “restless”, there was also a main treatment effect but the only 
statistically significant difference was between GR 68755 with amphetamine 
and GR 68755 alone. Subjects who received GR 68755 with amphetamine 
were more “restless” by 5 mm compared to those who got GR 68755 alone 
{95% Confidence Interval (Cl) 2 to 8; df = 66; p=0.002}. There were no 
statistically significant treatment effects on “feeling bothered” and “being 
treatedfairly”. See tables VII and Vm, and fig. IX.
Global Rating Scale
On the global rating scale, there was a significant difference between 
amphetamine alone and placebo (z = -3.51; p<0.001} and between GR 68755 
with amphetamine and GR 68755 alone (z = -3.62; p<0.001}. There was.
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however, no significant difference between either the GR 68755 and placebo 
group (z = -0.73; p=0.46}, or the GR 68755 with amphetamine and 
amphetamine alone group {z = -0.31; p=0.75}{see fig. X for the scores}.
Food preference VAS(B) and questionnaire, and the Test m eal 
paradigm
For all the visual analogue scales for satiety, there was a statistically 
significant main effect of amphetamine. Subjects who received amphetamine 
alone or amphetamine with GR 68755 both expected to, and indeed, found the 
meal less satisfying than those who received placebo. There was no significant 
difference between subjects who received GR 68755 with amphetamine and 
those who got amphetamine alone on any of the VAS. Compared with placebo, 
subjects who received amphetamine or GR 68755 and amphetamine felt less 
able to “eat a large amount o f food” before the meal, but after the meal, those 
who had amphetamine alone did not feel less full; however, no significant 
differences existed between the group which received GR 68755 and 
amphetamine and those who had amphetamine alone {table IX}.
There were no obvious preferences on any of the test paradigms on the 
forced* and *^ free food* choice questionnaires and the data is displayed in table 
X.
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Subjects who received amphetamine alone, or GR 68755 and 
amphetamine spent less time (in minutes) eating than the placebo group {(mean 
14.2 ± 1.6 Vs 18.2 ± 1.5; 95% Cl 1.5 to 6.4; t = 3.39, df = 23, p=0.003) and 
(mean 14.5 ± 1.1 Vs 18.2 ± 1.5; 95% Cl 0.2 to 7.2; t = 2.2, df = 23, p=0.38) 
respectively}. There were no significant differences in the time (in minutes) 
spent eating between the: (i) GR 68755 and placebo group {mean 18.24 ±1.2 
Vs mean 18.20 ±1.5; 95% Cl -2.3 to 2.3, t = 0.04, df = 24, p=0.97} and those 
who had the (ii) GR 68755 with amphetamine and amphetamine combination 
{mean 14.5 ± 1.2 Vs 14.2 ± 1.6; 95% Cl -4.0 to 3.1, t = -0.28, df = 23, 
p=0.78}.
On caloric intake, there was a statistically significant main effect of 
amphetamine. Subjects who received amphetamine alone consumed less 
calories than those who had placebo {estimate of treatment difference 
(estimate) -1846; 95% Cl -2648 to -1045, df = 23, p<0.001}. Subjects who 
received GR 68755 and amphetamine had a smaller caloric intake compared to 
those who had amphetamine alone {estimate -1946; 95% Cl -2736 to -1157, 
df = 23, p<0.001}. In contrast, there was no significant difference in caloric 
intake between: (i) the GR 68755 and placebo group {estimate 68; 95% Cl 
-716 to 853, df = 24, p=0.86}, and (ii) the GR 68755 with amphetamine and 
the amphetamine alone group {estimate -32; 95% Cl -834 to 770, df = 23, 
p=0.93}. The reduction in food intake by amphetamine affected both sweet and 
savoury items, and there was no sparing of any particular macronutrient 
{table XI and fig. XI}.
I l l
Computerized tests
On the RVIPT, amphetamine alone increased the number of correct 
responses per minute by 0.7 compared to placebo (mean 5.9 Vs 5.2; 95% Cl
0.3 to 0.9; df = 66; p<0.001). GR 68755 also increased significantly the number 
of correct responses per minute by 0.3 per minute compared with placebo 
(mean 5.5 Vs 5.2; 95% Cl 0 to 0.6; df = 66; p=0.03). GR 68775 with 
amphetamine increased the number of correct responses per minute by 0.5 
compared with GR 68755 alone (mean 6.0 Vs 5.5; 95% Cl 0.2 to 0.7; df = 66; 
p=0.003).
There was no statistically significant differences between the groups on 
geometric mean reaction time for both the RVIPT and SRT {see table XII}.
DISCUSSION
To minimize type I statistical errors, post-hoc estimates of treatment 
differences were only carried out if there was a main effect of treatment fi*om 
the ANOVA or ANCOVA. Confidence intervals have also been included vn the 
analysis, and differences were only taken to be biologically significant if the^ 
achieved the higher significance level of 1%.
While the ability of amphetamine to elevate mood and overall subjective 
state, induce reinforcement, and attenuate hunger were clearly demonstrated.
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the ineffectiveness of the 5-HTg antagonist, GR 68755, on these changes was 
surprising and contrasts with the findings of the previous experiment. There 
can, however, be several reasons for this discrepancy. It is conceivable that 
serum levels, and possibly central nervous system penetration, of the 5-HTg 
antagonist was higher in the pilot study (experiment 4) which used a repeated 
dosing paradigm in contrast to the single dose method in the present 
experiment; however, this cannot be confirmed as serum levels were not 
measured directly. Single dosing of this second generation 5-HT] antagonist, 
GR 68755, was employed because: (i) it has a shorter half-life than
ondansetron {for GR 68755 tm  = 1.6 h Vs ondansetron 3 h); (ii) peak oral 
absorption occurs within 0.75-1 h of ingestion; (iii) it has been shown that 2 mg 
given intravenously can reverse the cognitive deficits following scopolamine in 
humans (Glaxo unpublished data on file).
It is, however, conceivable that the answer, though more complex, 
might be related to the precise mechanism by which 5-HTg antagonists oppose 
dopaminergic neurotransmission. It is noteworthy that a single oral dose of 
ondansetron was sufficient to attenuate the reinforcing effects of a small dose 
of alcohol in previous experiments. It may be, therefore, that 5-HTg 
antagonists are most effective at reducing reinforcement when the drug of 
abuse depends, like alcohol or morphine, on intact transmission at excitatory 
5-HT] receptors, presumably located pre-synaptically on dopamine neurones. 
While this serotonin-dopamine interaction is quiescent under basal conditions, 
its activation by drugs like alcohol or morphine increases dopaminergic firing.
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In contrast, while amphetamine and cocaine cause the direct release of 
dopamine from the synaptic cleft and prevent re-uptake, they do not increase 
dopaminergic transmission through this transynaptic mechanism. Thus, their 
reinforcing properties may not rely on intact 5-HT activity at pre-synaptic 
5-HT] receptors. Nevertheless, this hypothesis can not account for the 
conflicting finding in animals that 5-HT] antagonists can block 
amphetamine-induced hyperlocomotion and CPP (Costall et al., 1989; Van der 
Hoek et al., 1989), and in some cases, fail to attenuate amphetamine (Carboni 
et al., 1989; Moser, 1992) and cocaine-induced behaviours (Paris and 
Cunningham 1991; Peltier and Schenk, 1991). In addition, it is possible that the 
effects of 5-HT] antagonists on drugs that release dopamine directly are not 
robust, or may be due to post-synaptic effects or interactions with other 
neurotransmitter systems which are at present poorly understood .
GR 68755 alone had no effect on any of the measures of mood or 
reinforcement, and this is in keeping with the findings of others 
(Costall et al., 1992). Amphetamine did not increase ratings of suspiciousness 
significantly, suggesting that these effects in psychotic patients may be 
attributed to chronic use, high dosages, or idiosyncratic reactions (Connell, 
1958). The increase in restlessness when those who received GR 68755 and 
amphetamine were compared to the GR 68755 alone group contrasts with the 
results of animal studies which have suggested a putative role for 5-HT] 
antagonists as anxiolytics (Jones et al., 1988) but is in keeping with the results 
of a recent preliminary study in humans where the 5-HT] antagonist BRL
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43694 failed to block the anxiogenic properties of the 5-HT agonist, 
m-Chlorophenylpiperazine (Silverstone, P; personal communication, 1993).
In the present experiment, I confirmed the findings of other investigators that 
amphetamine has anorectic properties in humans (Blundell and Rogers, 1980; Silverstone 
et al., 1980; Blundell, 1985). However, only one small study with 12 human subjects has 
examined the effects of d- and /- fenfluramine and amphetamine on macronutrient intake 
(Goodall et al., 1983). Like the present study which employed 26 subjects, amphetamine 
reduced the intake of all macronutrients. In contrast, (/-fenfluramine selectively reduced 
the intake of carbohydrates but not fat or protein from all foods. In addition, when sweet 
and non-sweet foods were examined independently, /-fenfluramine reduced fat and 
carbohydrate intake fi-om non-sweet foods but (/-fenfluramine did not reduce 
carbohydrate intake from sweet foods. Neither d- nor /-fenfluramine reduced protein 
intake.
It is of interest that GR 68755 enhanced cognitive processing in normal 
human volunteers, by increasing the number of correct responses. This finding 
is in keeping with the suggestion from preliminary animal studies that 5-HT] 
antagonists reverse the deleterious effects of scopolamine on cognitive 
functioning in animals and humans (Domeney et al., 1991; Glaxo unpublished 
data on file) presumably by facilitation of cholinergic transmission. Further, in a 
pilot study in humans, ondansetron improved age related memory impairment 
(Crook and Larkin, 1991). While amphetamine also increased the number of 
correct responses on the RVIPT it did not improve reaction time on the 
computerized tests. This differential effect of amphetamine suggests it may 
improve sub-optimal performance due to boredom or fatigue, presumably via 
increased catecholamine release, but may have little effect on maximal 
performance (Weiss and Laties, 1962). Interestingly, the cognitive enhancing
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properties of GR 68755 and amphetamine were not additive suggesting the 
response might already have been maximal.
14. GENERAL CONCLUSIONS
1. In humans, like animals, it appears that the reinforcing properties of alcohol
may be related to its ability to facilitate dopaminergic, transmission via excitatory activity at 
pre-synaptic 5-HT] receptors. The present thesis provides the first clear 
evidence in humans that the 5-HT] antagonist, ondansetron, which opposes 
dopaminergic transmission in the nucleus accumbens, can reduce the 
reinforcing value of alcohol. Importantly, it has also been demonstrated that the 
effects of ondansetron on alcohol consumption could not be explained by 
possible pharmacokinetic interactions. Notably, alcohol consumption was not 
measured directly and in this respect it is important to point out that there is 
evidence, from the study of other psychostimulants such as cocaine, that 
attenuation of its reinforcing effects might, paradoxically, increase consumption 
and the subject works harder to obtain the reinforcer. In future, I intend to 
investigate which dosages of ondansetron can cause a measurable decrease in 
alcohol consumption in normal human volunteers and alcohol abusers using the 
present human laboratory paradigm. If these studies are successful, this 
research will progress to clinical trials.
2. It remains unclear whether 5-HT] receptor antagonists attenuate the 
reinforcing and mood elevating effects of psychostimulants such as
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blockade of dopamineamphetamine which cause the direct release and 
nerve terminals but do not increase dopamine neurotransmission 
transynaptically. Clarification of this issue would require a dose-response 
experiment, perhaps with repeated or parenteral administration of the 5-HT] 
antagonist. The potential cognitive enhancing properties of 5-HT] antagonists 
deserves further study, particularly in relation to the age, and possibly, 
disease-related memory impairment.
3. 5-HT] receptor antagonists on their own are without apparent effects on 
mood and do not induce reinforcing behaviour. This suggests their abuse 
liability is low, an issue which may be of critical importance if they are to fulfil 
their promise as being useful in the treatment of drug-seeking behaviour.
re-uptake from
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nisoxetine, 32
NMD A receptor sites, 29, 30, 51 
non-conditioned response, 33 
noradrenergic pathways - locus coeruleus, 31 
nucleus accumbens, 41, 52, 62, 70
O
ondansetron, 54, 72 
P
Para-chlorophenylalanine (PCPA), 26 
paraventricular area, 37 
perifomical area, 37 
priming, 20, 58
Profile of Mood States questionnaire (POMS), 60 
propanolol, 36
Q
quinpirole, 60
177
R
rapid visual information processing task (RVTPT), 104 
reinforcement, 60
drug seeking behaviour, 18 
learning, 18
lever-pressing for alcohol, 27 
positive reinforcement, 18 
reward, 20 
reward thresholds, 21 
S
scopolamine, 63 
self-administration, 60 
serotonin (5-HT)
2-methyl-5-HT, 51, 56
5,7-dihydroxytryptamine, 55
5-HT pathways - median raphe, 26, 42,
5-HT pathways - dorsal raphe, 26, 42 
5-HT/dopamine interactions 
5-HT2 fibres, 42 
5-HT] agonists, 56 
5-HT] receptor antagonists, 42, 56 
5-HT] receptors, 114 
5-HT3 receptors - pharmacology, 45 
5-HT3 receptors and cognition, 54
5-HT3 receptors antagonists and normal human behaviour, 46 
simple reaction time task, 66 
Stroop colour naming task, 87 
substantia Nigra, 44 
sucrose, 56
T
T-maze reinforced alteranation task, 63 
type I statistical errors, 113
V
ventral medial hypothalamic (VMH) lesions, 55 
ventral pallidum, 42 
VTA, 41
VTA and reinforcement, 28
178
ii l
! l î
i l l
I I I
® al
II!C - O
f i l
il!
il!
h | 1
ïiî
c
«I
îii
<  o ^
I
'Sen
II
E
•s
ô
I
m
o
o
o
œ
o
o 'ON
fS
O
r^Tf lO
d
00
o
o
o
o
2  :
Q.
CL
k
o fS ON »o o oo fSr- ON fS i/j ON ON ON o ON
<s fri fri fri d d fri NO
'O
fn o\ ON V) o ON o o
o w o O o o W 'O o
d d d d d d d d d d
<s es oo »o o fS V) 00 fS
'O 00 fn o
fS fri fH w fri fri d fri
w
fn o o rr
r- o »o o o oTf o fn o o o o o
O rn o o o o o d d o
d d d d d d d V V d
'O
N
O o\
rî rî
m
m
Os00
iri
«s
d
o>
301)O
"5g
"rt 
3  •en îS
c
•3
«S
e
o
U
M)
b
e
W
3
§
0£
a,
O
30)
3
S
u
3
G
z
30>4>
M)
<
gM
e
o
U
3
0>
X
_3
Z
PC
NfS
C
c
3
.fe
t
I
o
t^.11
Lw
O
k
$
3
I
I
f é
i l
•S ü
& E
II §1
il
3  C
1-13  %
O A
P
il
g . |
P
H*5
e
3
S
2 ®  s  
Ë 4 -S
l ü ô
U  <  I
f l
z  J O
U
Si
u
o
2 e  V 
1 1 =
u
3
I  *
% 2  
M <
â I
< q3 0
V
<
I
so
u
V)
o
I
I
I
S
eI
VO
II
Z
II
Z
II
Z
NO
II
Z
S ' s !  _
3 3 3  "ZT O
Tf
r î
w-
©
Tt' ©
*
r-
©
m
m
fS
iH 00 ©
*
*
O
#4 N#4
*
*
M ©#4
*
*
rT
V)
vT<-r^
00
kv«
©
d
ON
•rT d*-y^
00
m
m
s
r-
©
m
©
fS
©
en
B
1“^m
m
m
*
N
00
V)
©
vT
N
rT
V) fS
00 «s
m M «O
m
.2 c 3  £
o>DC
g
C
W
30»
X
_3
Z
PC
00
1
a
£
V)
u
o
JS
u
M
£
2
3D
<
%
C
OO
*
n
oo'-v^
ITi
m
ITi
g
3
«S
Co
u
•T)
rT
kv"
N
V)
kv"
«s
r4
rT
r»
©
so
<s
fS
3
3
2
J3
L,
2
0
g
c
2 ®  B
■La
w < .
3J«î — B
g c w
1 1 =  MO .
V3
I  '
s  2 
U c
i I
Ie
O
u3
U
U
ir>o\
U
u
ON
B
S
s
\oB 3« Il
S  Z
g -
ü  IIs  z
g s« Ils  z
i
S
a
I
S ’s !
lîitl I
en
B
i/î
V)N
V)
fS
S
«s
uri
N
*
*
©«S
M
00
fS
00
.o
II
*
*
Tf
oT
*
\o
©
m
«s
r î
*
*
<N#4
N©
0\
00
fS
s-w
BO
U
i
M
r f
V)
00
Tt
oT
*
*
o
rlT<-v^
©
O n
fS
u
■wen
I
a
O
lf«l•t. -o 5 
®
f i® 3 OII
Z
l l î l
III'--
Ê
3  5 3 C g
1 1 1
11-!
I l l
U O u
I
3
i
g3
g
O
« "S
iilifi
B -C
il!
Il
: :
= §  k
- s
l < l l l  I I "
k
i|i!0> .B 
^  ^ O
II«/>© Il s  -fl ü- g  en «  O
X "2
li
«3
gj 3
îî
3  ^
.gzM
II
$
..■s -  “ ■ 
§ = “ 1
% 
2i
li
1 1
!î
H
g s
S £•II
■3 o.
I -ecç
è
•So
'lifi
3  o
Ç.S S - f l
i i i i w«5Ü
%
<
3 §
g a
^ c  0) o  
s  k
f s
iîi
Il °
i î î
Pi3 G.S
!lî2 "  o
S g-S
I #
® 3  O
IS
a ^ l
31 i
H o  o
a
3
II
c
so
Q,I
I
3
0  M)
1
k3
O"
«
■S
s
0>
M)
i
<w
I
r
•g
s  s
S I
2
II
Z
2 (S
II
Z
mvo
r-Tf
nTf
00
d
so
m
N
OO
fS
1^
m
m
fS
P. s
oso I/)
!5m
m
m
V)
soN
SO
Z
2
M)
k0>Of
m
3Of
3
2x:
k
2
S
tri
tri O <S m«s m
tn
U U
B
Of
3
«S
BO
U
r>-
m
sotn
tn
%
#
tn
s•w
BO
U
3
l î
mI
O.o
g
B
3
3
§
O
£
Z
3D
B1
3
3
B
3
Ox:
8
LZ a"g3D k 
B 3D
1 1
H
M
Of 3  
£ &
11
k
B
I
B
Of
01
g
B
Of
B
a
3
3
Of
3
B
i
I
B
g
3
1
B
2  
Of
k
3
3cr
g
«2S
s î
> B
% 3  Of1|w
I s
00 JS
1 3
3 CL 
3  jS
II
k 2
3  3
§ e
i l
«  g
i l
II
>  00
“ • sOf ^H
ON
Tf m 00
© Tf fS
© © ©
N
I
I
3
B3
0
1
00
B
2
Of
k
gor
g
B3
3
Of
< s
0
1
§
3
g
II<  00
<N
II
Z
Of00
B
2
k3
9
O"
b
2 fs
3
I IIZ
s
f i
B
2
Of
00
<
tn ve fS r4oo
< soo
© 00 NO Tf 00 00 00
ON r - © 0 \ 00 m ON On
© © fri fri fri
9
«S
i  s
i
N
N
3
CQ
^  © 
m  ^m fn
s
fS
< s
k
Of
Of
B
u
s
3
3
2
k
2
ü
I I I
2
<S
g3
«S
B
O
U
00
tn
fS
g
B
O
U
K
£
2
2
O
S
R
r» 0\
3  9
;
B
.S
3
U
zI
CLo
g
B
E3
B
Of
g
B
Of
B
CL3
3
3
B
i
i
B
I
1
i
Of
k33
©
g
3
B3
en
I3
I
00cI
0  u
z
E
3
1
a  ^
s i
HOf -M
g  %
= 1O
«5 3
lîi
■ a i -
g
U ô  O
| 200 
E
s
£•■§_ 
i|t
^ i l lOf %
£ Ï l“ 3 0^  — 0 \ 3
C
L
î ï
li
2
CL
E
Of
â  £
Of «J g,
IIOf O 
2 :  
11
1 1
£ s
l - r
il
o
11
1 1
2 ô
P î
I h
llï
S
2
OfV3
II
1 1
S O
pf
« “ o
e j s
l l î
u
#
V)
ON
Of
en
-H
3
3Of
S
Of
en
-H
C
3Of
S
00
II
z
00
II
z
o
BOw
z
o
a
NO 00
1—m 
NO 00 Xf)
w fri Tf tn d fri
»o fn © fN
fn ON 00 iri d tn d
fri fri xri
fn NO Tf fn 00
© © ©
f*^  fn ON ^
©  <s fri tri rô fri fri
+1 +1 4-1 +1 +1 +1 +1
Tf ON ©■: ©  »o o\^  fn 00 ^  ^  ^  ^
so VI NO
© #4 v4
44 44 44 44
On Tf t"
fri d oô
NO fS
fri*-»- fri fri
4-1 44 4-1
d OÔ00 ^  ^  ^
in <s *ofS ©fn
CL
3
3
3
3
O
C
3
E
3
§
2
3
3
E
■g
3
Of
g
CL
3
3Of
3
3
30
1
B
Of>
3
B
î
I
3
Z
s É
l i
£
H
Ill
o
B
i h
IP
i l l
n s h l  
n m °lülii
= 1
i l
so
■*Êfà
3
il3 U
II
i l  
i l
1-f«■SIIen g»
3 2
if .
Il llïîi^si
?s|
1 1 1(Z 3 o
|s
CQ w <2 Id § E
e s
§# 
3  2
lî
U*5
ii
INIilC/D o «ta 3 o w
m
E
Of
-H
Cs
s
E
Of
en
-H
B
S
s
eu
ûT
E
Of
en
ta-<
-H
S
2
S
E
Of
-H
S
2
S
00
II
z
e fS fS
d d d
• rv • •V • •Kr- 00 V)
d d d
o 00 00
d d d'-y'
+1 -H -H
O 00
d d oôn fS n
os
fri d d*-ta ta-
-H ■H +1
00
II
z
'C
d
m
00
II
Z
00
II
z
^ l ' ­
i l !  s
00 V )
os
00
O
ris riT
d d d
NO 00 00
fri fri dta- ta- ta-
-H -H +1
00 O
d tri d
fS <S m
ve fS
d fri frita- ta—
-H -H -H
fn
d oô tri
V )
n
o
m
GOf
* s
!
Of
§
2U
O
V
0
%
1
0£
B
1
3
1
2 
Of
I
en
§
%3
Z
fc
O
U
tOfta*esI
Of
1
3
JS
S
s
§
a,
3en
3
S
3
a
§
Vf
Vf pZ
i w
a«I
s g ' T
|S§ I
V )
U
Si
u
Si
V )
On
* *
* * * «
* * —ta —ta *
r“ta
r - r - w 00
ri V f ri
ta - ta - ta-
Tf V f t" On V f
en en en en
B S B B B
• •s
—ta —ta
ri m V f V f V f
ri ri Tf m w
ta - ta - ta­
e e e iH ri
en en en % en
B B B B B
• •s • - • - • -
—ta —ta —ta —ta
ri ri V f Tf m
ri m m m
ta - ta- ta - ta- ta -
o o o e o
*
*
ena
fS
vT
m taH
Tf
œ
en
S
Tf
vT
Tfta—
r -
en
C
V f
m
en
S
V f
Tf
Tf
Tf^
Of>
g
Of
5
6 
3
a.
E
3
3
3
3
1
o
I
M
Of
Z
3
H
V
3
a  •II
a
E
3. J
a.
E
3
"Q
V f
V f3:
Of
« S s -
ilil
U
V f
On
B
S
s
B
I
B
I
i
* *
« * * *
* * —ta
r ta —ta ri m
r- r-
ri ri V fta- ta- ta- ta-
Tf Os
en
B
NO
(S
e
V f
V f
V f
Tf
V f
Tf
Qen
1 1
O
V f
V f
V f
Tf
V f
Tf
QO
00
Tf 1-H
V f taH
m
V f
k
Of
Of
B
U
3D
B
1
3
B
TfTf
Tf
Tf
enen
Of
en
Of
BS
*
*
T f
r f
taH
—
00
V f
m
'O
« s
T f
Tf
Tf
Of
‘3d
k
3
Bta*
Of
*
*
i-ta
Tf
V f
Os
ri
ta-
r -
00
ri
taH (ta
^  taH
3
g
OfD
B0)
S
0)
I îOf gf
fK k
N
N
3
n
Vf
wo k
III: *UV f
a  
B
3
t a  tta I
II!
V f
l - J
I S "
il
u
V fOs
u
#
Si
u
Si
Q.
E
3
% g
I
a
E
3
*3
Vf
Vf
S i
I
B
I
B
I
*
*—taTf
r f
en
B
m
en
B
Vf
rT
*
*
—ta
V f
o
m
@0
Tf
NO
Tf
0>
3
B
i l l
3  Çgillil
0» ^  
^ t 'II
kOf01)
B
3
K
*
«
NO
V f
en
B
NO
d
en
B
NO
m
*
* 
NO
vT
0\
ri
ro
m
ri
Tf
en
B
m
s
ri
r f
ta-
o
%
B
m
ri
00
00
B%
■?
0£
æ I
en
B
©
ri
%
B
ri
00
enen
Of
B
en
a
% 3
s  3 s
ce Ek B
NO
NO
V f
o
Tf
o
Tf
O
%
s
Iî
H
S
©
Vo.
êf
:
V f
s
B
ei
£ “ ■
■ o -
il
i :len Of
i £ ^
Îïî
'■ • l i
fil
îîi
3  Of 00
g b 'z
« • I
en
3
en
1  S
a :
-  gIII
l l f
M o J
ü î t  « Ii_._E Si l
f
4
:-iÊi
O
O
3
_0f
1
I
l i t
" .2 "  
s i  «■
il
en
s
i
I
O
‘S
5?’l
_ g 
% 6 
e i
3D 3 
O
11
11
k
le S
m  Gi'E
o s  
s o
tl
C3 u  
> 'C  
- 1 
31
S1
il
o,
l i '
a
a
Z ben
3 ^
B
I
C/D
<
>
a
2
I
Q
I
O
V
r*
m m
ta ta ta 00 taO § O o OO O o O
d
V i
d
V
d d
V
•rio NO r i
5
or i tri t^ r i
dta ta Tf dta
fTf fTf fTf fTf
r -
m
Tf
®
O
mo
fri
«o
%
NO
ri
d
«o
§
o\fri
fS
§
Os
iri
a@f
3
Cae
U
BC
Ik
3a
W BDI I
O
V
NO00
fn
Tf
O
fri
<sTf
V)
VO
1BC
4f
X
<U
g4»
E%Vf
I î4) 4)
X  b
o
o
d
V
Ovl>
fn
r -
o
fnTf
<s
fri fri
fnm
fSo\
o
®
o
V
00Tf
fn
r -
m
V)
o
o
0\
o
(ri
s
OQ
•c
Q
»
e
&BO
O
9
S
V)
oTf
fT)
fn00
Tf
00
o
®
oV
VOVf
fri
S ’
ICA
Vf
VO
TfVf
m
o
V
TfVf
"2
&ja
©
o
Vf BO
1 Ice b
fSta
d
ri
fri
o,00
o
V
Vfr~ ta
r iTf
.h9
1
î
H
Tf
r i
II
a
2
15*
3ce
NsdNO
d
II
a
3
3
k
Otk
31 1
V)tn
PC^
ÜpLf
0>s
z
> so
ri
3
3 ta
k %3
*3 ta
PL ta
0%
V)
PC ^ "Q 
0 3  X
V)
m
ri so
m
ri
t"
0>
%
2
£
%
<
>
i
8
3
3
3D
O
Zs
3
Z
3
.2
>
§
Vs
S
3
O.
I
3
3e
3
V)V)
S
PC
O
*o
09
3
1 1
3
.S I
°3
Krr
:N
X
o.
w E
( 2 f  ! ■ !
CL V f 
g Vf
■l+Si
CL
E
3
*3
V f
V f
o i
V
3
E
3
en
-H
i
s
E
3
en
-H
I
6.
3
en
-H
I
o>
3
Z
>
3
Z
>
Tf
ri
II
Z
Tf
ri
II
Z
I ‘
M
I 4S  -H en
V f
ri
II
Z
Tt
ri
II
Z
V f
m
m
-H
§
X
4f
Z
H
1
ce
<
>
ooo
d
V
V f L—,
Oo o
d
V
V f L— ,
ri
Tf
Tf
eoo
r-
m
osso
m
+1
R
ri ri
-H vT -H
w d r*NO V f
ri ri
-H -H
r> ri
o o
H4
o 3D
O
V
fri’
Vi ViVi
d d
ri Tf
-H
O
Tf
ta
ri
d
-H
%
vTri
d
ôc
d
V f
oe
ri
ri
3
S
è
An fill
r i l |  
t l f ï
5  .
3 3
i l
tntn
I s  S j
î î  gs
l l  
£  z
V)Vf
3  ®® Q. y
II i l !
3
II a  B3 CL 33
.Âai
a
E3
3
V f
V f
S i
u3
E
d
en
44
S
I
E
Hen
4-1
I
E
d
en
44
1
2
a
k
a
Cl
CL
k
s •«i «ü
S  4-1 e«
S
3
4>3
Z>
Tf
r i
II
Z
Tf
r i
II
Z
V f
r i
II
Z
Tf
r i
II
Z
Tf
©
QO
r i  I—j
Tf
44
ri
V f
Tf
44
r>
V f
Eë
ce
ri
44
S
r i
4-1
Ol>
Qi
« 5
I :
en%
An ta E
ri
ri o o \
d o d
00 00 Tf
o Tf
d d d
t a
©s O
e O
d • dri
Tf
O t ao r - O
d dri
r -
T»
d d
ri
ri _!_{
V i
d ri dr-
ta
eoo ri
d oe
V d
ri
m 4-1 ©ri dri 00 ta
o
t a ri
00 ri
d d
ri
o cT
e os
d 00 d
N— ' r*
ri
44
t"
r-
3DC "3ta
ta
en Of
Qita
3
en ta
X
s  r i  Qi r i
*5d " 
2 %
3  r i
1
3  o  
B
K git
PC wi
o K=!MflS
dT®
II
î t
K s
i - s
S i
s -
ll
E " e
S=S2
il!
Il
^  C'%
l l
2 2-2.:::
0 
3
1
E
3
I .
2
i
l l î
V)
i
PC
o
3 3
II
1
i!l
i h
ï î lV — Otn
| : i
SIî i l
a %
I I S s
a
ri(Â
-H
$
O,
S
?3
r»
S
Xo
B
riCÂ
-H
i
Z
8
ri%
+1
I
w•ta QO
II
lîb  u
8
ri(À
-H
I
S
Tf
«S
II
z
Tf
«S
II
Z
V)
<s
II
z
«s
II
z
T f T t Tf Vf
-H
e d d d
+1 +1 4-1 44
ta Vf Vf T f r i
ta Tf V f
d d d d
44
44 4-1 4-1 44
ta V f V f Tf Tf
T t
ta T t T t T t V f
d d d d
44
4-1 4-1 4-1 4-1rita ri T f ri ri
ta Vf V i r i Vf
44 d d d d
Tt 44 44 44 44ta
r i r i r i r i
1
4i
U
*o
■g
■9 .s
V
*o
6 "5 ^ *5W ta  V tak o 4) o
r hî iïCl fi. Cl fi. k
Oi
3
■ë
►»
€
B
k
3
U
3D
k
3
S
I
nJ
s1
! •
s
g
%
e .S•I I
i Ib i  0^
I  3 + 0  
3
g Of
I I  II
g
S
E VfI gJS NO
a
s r i 00 r i r i r i
ri ta V f 00 Os r i r i(0 V f Tf ta OS ta ta V f ta Tf Tfr i O 44 so ta r - 4-144 44
44
44 4-1
Vf 44 -H 44 44
Vf 5 e r i so V f V f
S Os r i r i © e Tf 00 Tf Tf Tfw Tf o ta ta V f so Tf 00 00>o 3c ta ri ta V f ta SO ta ri ri
X
o
E■I
3
g
I
g I
% i
S
riM
+4
a
2
S
8
ri(0
+1
S
s
8
riCfl
+1
I
s
IU
Tf
os e
1^ Tf r i OS ta or i SO ta V f ta
44 44 44 44 44OS
V f r i so Tf O r -
3* ta 00 r i r i r fta r i OS V f ta
e ta
Tf
Tf
ta
r i r -
-H
44 44
so 00 er iOs 00 r ita Tf ta
s
-H
§ri
Tf
m
44
QO
C
O
X .t:
g
"O
G
O
U
S
ko
3
U
î
uce
:  *  Os r i3" ta
3k3>»
1
à 3
r ir i r ie ta 00
44 44
44
r - V fr i r i sota 00 o
00 ta ta
Tfr i V©
V f ta 00
V f
44
O
33
•£.
I Ice CL
44 44
£Tf ^
:  :  so V f V© ta
K
r irf
Tf
4-1 4-1
r i
r it^ sri
ta so ©V© r - Tfta ta r f
44 4-1 44 4-1
OS V f e r iO N© V© r io r f r i r -ta r i r i V f
r i so r~r f t> e
ta ta ta r i
SO 44 44 44
44 r i e ta
Tf r i o
00 r i Tf soos r i r i V f
b
Ik3>»I 3
U H
o
Cl
a3k3
•g
Bta ^
£  u
H
ssce
li
R
S
ri(0
-H
a
2
S
Tt
«S
II
z
m ta r i r i Tf
ta e d d d
44 44 4-1 4-1 4-1
r - O r i r i r i
aa9
3
S
«iC0
-H
Tt<S
II
Z
r i ta r i r i Tf
ta d d d d
44 4-1 44 44 -H
r" ta r i r i r i
V)
i
Xe
e
©9*W
9
a
ri<0
-H
a
I
a
ri
-H
s
s
V)
<s
II
z
Ttfi
II
Z
r i ta Tf r i r i
ta d d d d
4-1 44 4-1 44 44
© O ta ta r i
r i ta Tf Tf Tf
ta d d d d
-H 4-1 44 44 44
r>- O ta O r i
X
ai 3
il
Ci
u
oJi
-O %5
§ §  b  u
Ss
I
S
5
V
s
'o
B
I I  I I
g £  2 2
Ek Ci, Ek a £
3
U
3
Ik
3
U
I
S
I
at
u
S1
£
ë
Q,
2
I
t*m
0
s1
II
aI
a
B
3
3
ai
.B
BIëI3
3
V)
V)s
£
WO-à
a wf Ë W)
I . S i
I
3 îi
V) C
U;
C
ll
g
K
5
K
e
$
K
ll
a
z
?
Z
ü l
o §
1 1
M I
S i
s i
V)
e
eVf
00
o
Vf
H 8 ü i
ri
O
• ©  ©©  m-i—J
r i
©
OSos NO 
©  ©
r i
©
Os
• ©  ©  ©  I
©
©
Tt
t"Tf
rf r~ 
Os r-  
T t T f
Tf00
Os
T t
!3
tn
&
B
r f
I
BI
î
©ta
r f
Vf
ta
r i
r i
r i
r i
r i
r i
r>
i
n
S S ’
. o ©©  ta-L—I
• ©  ©© ta-1—1
©ta
r i
r -
ta
r i
r i
r i
r i
r i
r f
I
&
B
m
0  3
2
01isr i
©
ta II
kSB
«2*3
• ©  ©©  ta- u—1 I s
r—— S I
r i ■ ? «© «  2ta %
C ta
3  O
s s î
s i
• O  ©©  ta-i—1
r i
en gf
3 taai 3
il
3  3
• g »
■° «
en 3
1en a«g^ 3
3 o 
C
•Il
1 1
il
II
w o>
li
g> ai MB
Fig.I. Mean change (mm) In visual analogue scales (VAS) for 16 
subjects who received four treatment conditions: (a) alcohol and 
placebo ondansetron (ale); placebo and placebo (plac); placebo 
alcohol and ondansetron (ondan), and (d) alcohol and ondansetron (ale 
& ondan}. Alcohol (3.6% alcohol content by volume of lager and 20 ml 
lime juice) or placebo alcohol was given at time “0”, 60 mln following 
ondansetron or placebo ondansetron. Aster Iks show significant 
differences between alcohol and placebo and alcohol and ondansetron, 
*p<0.05, **p<0.02, ***p<0.001 (post hoc one way analysis of variance)
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Fig. II. Medians of the area under curve analyses (AUC) for 
change in self-ratings of subjective mood following alcohol 
In 12 healthy males pre-treated with ondansetron or 
matching piacebo
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Fig. III. Mean serum alcohol concentration In 8 healthy 
males who received 580 ml of 3.6% alcohol content by 
volume of lager + 20 ml of lime juice following treatment 
with ondansetron or matching placebo
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Fig. IV. Mean change from baseline (In mm) for self-ratings 
of hunger In 9 healthy males following either placebo and 
placebo, ondansetron and amphetamine, or placebo and 
amphetamine. * Significantly less than placebo and 
placebo, p<0.05, paired t-test. + Significantly less than 
ondansetron and amphetamine, p<0.05, paired t-test
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Fig. V. Overall subjective state In 9 healthy males who 
received placebo/placebo, placebo/amphetamine, or 
ondansetron/amphetamine. Both ondansetron/amphetamine 
and placebo/placebo scores were significantly different from 
the placebo/amphetamine group (+p<0.05, Wilcoxon’s  signed 
rank test).
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Fig. VI. Change in time taken to answer the Stroop colour 
naming task in 9 healthy males who received placebo and 
placebo (piac), placebo and amphetamine (amp), or 
ondansetron and amphetamine (ondan & amp). For 
subjects who received placebo and amphetamine or 
ondansetron and amphetamine, significant differences 
from the placebo and placebo group are shown as *p<0.05 
and **p<0.02; paired t-test
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Fig. VII. Change in mean reaction time in 9 healthy males 
who received placebo and placebo (plac), placebo and 
amphetamine (amp), or ondasetron and amphetamine 
(ondan & amp). For subjects who received placebo and 
am phetam ine or ondansetron and am phetam ine, 
significant differences from the placebo and placebo  
group were shown as *p<0.05; paired t-test
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Fig. Viii. C hange in m ean sy s to lic  b lood p ressu re  in 9 
healthy m ale vo lun teers w ho received  p laceb o /p laceb o , 
ondansetron/am phetam ine, or p lacebo/am phetam ine. For 
b o th  p la c e b o /a m p h e ta m in e  an d  o n d a n s e t r o n /  
am phetam ine, sign ificant d ifferen ces from the p laceb o / 
placebo group are show n a s  *p<0.05, paired t-test
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Fig. IX. Weighted means (mm) on visual analogue scales (VAS) for 24 subjects who 
received: (a) placebo + placebo {placebo}; (b) GR 68755 + placebo d-amphetamlne 
{OR 68755}; (c) d-amphetamlne (d-amp) + placebo {D^mp}; and (d) GR 68755 & d amp 
{GR 68755 & d-amp}. GR 68755 (2 mg orally) was administered 30 mln before d-amp. 
For graphs, d-amphetamlne (20 mg orally) was administered at time “0”, and there 
was a significant effect of d-amphetamlne compared with placebo.
p<0.001 {paired t-tests}.
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Fig. X: Effects of GR 68755 and d-amphetamlne (d-amp) 
on global ratings of subjective mood In healthy males
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Note: subject 14 received GR 68755 in two periods, 
with a score of 1 in period 1 and 0 in period 4.
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A ppendix 1a: Sam ple visual analogue s c a le s  on m ood and 
the desire  to drink for experim ent 1 
V isual A na logue  S c a le s  
S u b je c t  ID  S e s s i o n   D a te   T im e
I feel co n fid e n t
N ot a t  all
1 feel ch eerfu l
E x trem ely
N ot a t  all
1 feel e n e rg e tic
E x trem ely
N ot a t  all
1 feel re lax ed
E x trem ely
N ot a t  all
1 feel a g re e a b le
E x trem ely
Not a t  all E x trem ely
XXIX
1 feel optimistic
Not at all
1 feel clear-headed
Extremely
Not at all
1 feel optimistic
Extremely
Not at all
1 feel like a drink
Extremely
Not at all Extremely
XXX
A ppendix 1b details the volunteer screen in g  procedure,
in clu sion , exc lu sion  and withdrawal criteria, and stu d y  day
restrictions for experim ent 5.
Volunteer screening
• A medical and history and examination, and a psychiatric interview 
was performed in the two week period prior to each subject’s first 
dosing occasion.
• Blood pressure (BP) was measured at the screening visit using an 
automated BP monitor. Subjects rested supine for 15 minutes after 
which three readings were taken separated by 5 minute intervals. 
Subjects were excluded if the mean systolic BP was greater than 
140 mm Hg or the mean diastolic larger than 90 mm Hg.
• Laboratory safety tests (haematology, biochemistry and urinalysis) 
were performed at the screening visit, and a urine sample obtained 
for drugs of abuse including alcohol.
• In the one week period prior to the first dosing occasion, subjects
were required to chose what they would like to eat during the test
meal from a list of food items (see appendix Id).
inclusion criteria
• Male volunteers aged between 18 and 45 years who are in good
physical health and who have no history of mental illness or
substance abuse.
x x x i
Exclusion criteria
• Participation in a study within the previous four months.
• Being in receipt of a regular course of medication four weeks prior 
to the study.
• Consumption of more than 4 units of alcohol per day (1 unit =1/2 
pint of normal strength beer, one glass of wine, or a single measure 
of spirit.
• Consumption of more than 8 cups of caffeinated coffee per day.
• Smoking more than 8 cigarettes per day (or the tobacco equivalent 
per day.
• Body weight greater than 100 kg or less than 60 kg.
• Vegetarians.
Withdrawal criteria
• Unwanted effects from the study drugs.
• Inter-current illness requiring medication.
• Abnormal laboratory tests judged to be of clinical importance.
• Subjects not wishing to continue with the study for any reason.
XXXII
study day restrictions
• No caffeinated beverages or smoking 12 hours preceding dose or 
during the study
• No alcohol for the 24 hour period preceding dose or during the 
study period.
• No strenuous exercise on study days.
• No concurrent medication on study days.
• Volunteers should not drive, cycle, or operate machinery for 24 
hours following dosing.
XXXIII
Appendix 1c: Global rating scale for experiment 5.
Volunteer Number:--------------------
Occasion Number:---------------------
Date:-----------------------------------------
Global rating Scale
Please circle your response
HOW DID THE TABLETS/CAPSULES MAKE YOU FEEL
0 - NORMAL
1 - SLIGHTLY LIGHT-HEADED, RESTLESS, OR SPEEDED UP
2 - MODERATELY LIGHT-HEADED, RESTLESS, OR SPEEDED UP
3 - VERY LIGHT-HEADED, RESTLESS, OR SPEEDED UP
4 - LIGHT-HEADED, RESTLESS, OR SPEEDED UP
Please enter any other comments you may have below:
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A ppendix 1d: Food Items from which su b jects  s e le c t  the  
com p osition  o f their te s t  meal
Volunteer Number: ...................................... Date:..........................................
Please rate the following foods according to your preference below:
1 2 3 4 5 6
Dislike Neutral
Extremely
Bread:
 White
 Soft Grain (Mighty White)
 Wholemeal
Sandwich Fillings and cold meats:
 Cheddar Cheese
 Cottage Cheese
 Peanut Butter
 Ham
 Tuna Fish
 Chicken Roll
 Marmite
 Strawberry Jam
Chocolate:
 Milk Chocolate (Cadbury’s)
 Plain Chocolate (Boumville)
 White Chocolate (Milky Bar)
8 9 10
Dislike
Extremely
Biscuits:
 Rich Tea
 Morning Coffee
 Digestive
Deserts:
 Strawberry Yoghurt
 Raspberry Yoghurt
 Black Cherry Yoghurt
Crisps:
 Ready Salted
 Smoky bacon
 Cheese and onion
Fruit:
 Apple
 Orange
 Banana
XXX
A ppendix 1e: The ^forced choice' food questionnaire
Volunteer Number: --------------------- Occasion Number:------------
Date: ------------------------------------
Please examine each of the following pairs of food items one at a time and 
place a cross on the line next to one which you would prefer to eat at this 
moment. You must indicate your preference for one food item out of each 
pair.
A ro as t chicken — or—-
1/4 lb. grilled Rum p s te a k  — or—
A d oughnu t — or—
2 o z  of C heddar c h e e s e  — or—  
A dish  of tinned  fruit sa lad  — or—  
A bak ed  po tato  with butter — or—
2 oz  C h e d d a r c h e e s e  — or—  
A dairy king co n e  of ice cream — or—  
A baked  po tato  with butter — or—
Two p o a c h ed  e g g s  — or—
1/4 lb. grilled Rum p s te a k  — or—
A dish  of tinned fruit sa lad  — or—  
A ro as t chicken b re a s t — or—  
A bak ed  potato  with butter — or—  
A m edium  sized  grilled cod fillet-or—  
1/4 lb. grilled rum p s te a k  — or—
A large cadbury ’s  flake — or—
A ro as t chicken b re a s t — or—  
A doughnu t — or——
2 o z  of C h e d d a r c h e e s e  — or—
A diary king co n e  of ice cream — or—  
A m edium  sized  grilled cod fillet - o r —  
Two p o a ch ed  e g g s  — or—
A d oughnu t ——or—
A large C adbury’s flake — or—
A baked potato with butter 
A large Cadbury’s Flake 
A medium sized grilled cod fillet 
A diary king cone of ice cream 
Two poached eggs 
1/4 lb. grilled Rump steak 
A doughnut 
A roast chicken breast 
A medium sized grilled cod fillet 
A large cadbury’s flake 
A doughnut
2oz of Cheddar cheese 
A large Cadbury's flake 
Two poached eggs 
A diary king cone ice cream 
A dish of tinned fruit salad 
A medium sized grilled cod fillet 
A dish of tinned fruit salad 
Two poached eggs 
A baked potato with butter 
1/4 lb. grilled rump steak 
A dish of tinned fruit salad 
A diary king cone of ice cream 
A roast chicken breast 
2oz of Cheddar cheese
xxxvi
Appendix 1f: The *free choice'food questionnaire
Volunteer Number:-------------------------------- Occasion Number:
Date:--------------------------------------------------
Examine each individual item in turn to make your assessment. If you would like 
to eat
it at this moment place a cross on the line next to it. If not, go on to the next. 
Consider
each item independently from the others. Do not spend a long time on any item.
  A roast chicken breast
  A currant bun
  A large Cadbury's flake
  A medium sized peach
  A baked potato with a small knob of butter
  A medium sized grilled cod fillet
  Two average size tomatoes
  A grilled lean lamb cutlet
  A small size of cheesecake
  A small green salad
  A crusty white or brown bread roll
  Two slices of corned beef
  Four ginger biscuits
  A medium size sausage roll
  A dish of fresh strawberries
  Half a cup of tinned salmon
  Two pickled onions
  A small slice of jam-filled sponge cake
  A grilled lean piece of gammon
  Two lemon pancakes
  A medium sized dish of baked beans
  A carton of natural yoghurt
  One and a half packets of crisps
  A dish of shelled prawns
  A dish of tinned fruit salad
  A 2oz wedge of Cheddar cheese
  A 1/4 lb. grilled Rump steak
  Two sticks of celery
  A cream filled chocolate eclair
  A medium size bowl of rice
  A small slice of honeydew lemon
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A ppendix 2: G lossary of behavioural term s 
B ehaviour
Avoidance behaviour; Behaviour maintained by negative 
reinforcement; that is, responses prevent presentation of an aversive 
stimulus.
Escape behaviour: Behaviour maintained by negative reinforcement 
(see below) whereby responses terminate presentation of an aversive 
stimulus.
C onditioning
Classical conditioning: Procedures that present different stimuli in 
temporal proximity (contiguity) but where resulting responses have no 
reinforcing or aversive consequences (synonymous with Paviovian  
conditioning).
Operant conditioning: A procedure whereby responses have defined 
reinforcing or aversive consequences that are instrumental in 
attainment of a goal. Contiguity may be a necessary condition in such 
procedures, but is not sufficient for the procedures to be described as 
instrumental.
P unisher
A stimulus that decreases the frequency of behaviour that leads to its 
presentation. xxxviii
Stim ulus
Stimulus: An environmental event that produces a change in the 
behaviour of an organism.
Aversive stimulus: A stimulus which causes the organism to behave 
so as to minimize exposure to it (as in negative reinforcement or 
punishment procedures). In evolutionary terms, aversive stimuli were 
probably developed to enable organisms to avoid noxious or harmful 
stimuli.
Discriminative stimulus: Cueing stimulus, indicating occasions when 
a response will be reinforced. It is also the effect which enables the 
organism to distinguish between drug and non-drug presentations.
Relnforcer
Positive reinforcer: A stimulus that increases the frequency of the 
behaviour that leads to its presentation. Drugs of abuse are strong 
positive reinforcers.
Primary relnforcer: A stimulus whose reinforcing effect appears to be 
inherent. This stimulus is described as unconditioned, as it does not 
require learning or conditioning. Food and water are examples of 
primary reinforcers.
xxxix
Secondary relnforcer: A stimulus whose reinforcing quality has been 
acquired via its association with a primary reinforcer. This is a 
conditioned stimulus.
Schedule of reinforcement: A programme which determines the 
relationship between responses and the occurrence of reinforcing 
stimuli. Under intermittent schedules, responses are reinforced 
occasionally, and specified numbers of responses at particular times 
may be required for reinforcement.
Second-order schedule of reinforcement: A complex schedule 
whereby primary reinforcement occurs only after completion of at least 
two consecutive components each of which terminates with 
presentation of a brief stimulus that has typically been paired with the 
primary reinforcer.
Response
The behavioural consequence of presenting a stimulus to an 
organism.
Permission to reproduce behavioural definitions was provided by 
courtesy of Stolerman I and Elsevier Publishers.
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